

RiceBran Technologies
Form 424B3
November 17, 2014

PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(3)
Dated November 17, 2014 Registration No. 333-191448
(To Prospectus Dated July 15, 2014)

RICEBRAN TECHNOLOGIES

1,876,872 SHARES OF
COMMON STOCK

This prospectus supplement includes financial and other information derived from RiceBran Technologies' quarterly report on Form 10-Q for the quarter ended September 30, 2014 which was previously filed with the Securities and Exchange Commission on November 14, 2014. This prospectus supplement, together with the prospectus listed above, is to be used by certain holders of the above-referenced securities or by their transferees, pledgees, donees or their successors in connection with the offer and sale of the above referenced securities. This prospectus supplement should be read in conjunction with the prospectus dated July 15, 2014, which is to be delivered with this prospectus supplement.

FORWARD LOOKING STATEMENTS

This prospectus supplement contains forward-looking statements that involve substantial risks and uncertainties. These statements may generally be identified by the use of such words as "may," "could," "estimate," "continue," "expect," "anticipate," "believe," "intend," "plan," "will," or "shall." These forward-looking statements are based on current expectations and entail various risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth below and in our annual report on Form 10-K for the year ended December 31, 2013. We disclaim any obligation to update any forward looking statements as a result of developments occurring after the date of this prospectus supplement.

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

The date of this Prospectus Supplement is November 17, 2014.

The following information is added to the prospectus listed above:

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark one)

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2014

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number 0-32565

RiceBran Technologies

(Exact Name of Registrant as Specified in its Charter)

California

(State or other jurisdiction of incorporation or organization)

87-0673375

(I.R.S. Employer Identification No.)

6720 North Scottsdale Road, Suite 390

Scottsdale, AZ

(Address of Principal Executive Offices)

85253

(Zip Code)

Issuer's telephone number, including area code: (602) 522-3000

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12,

Edgar Filing: RiceBran Technologies - Form 424B3

13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes No

As of October 31, 2014, shares of the registrant's common stock outstanding totaled 9,374,082.

RiceBran Technologies
 Index
 Form 10-Q

| | |
|--|------|
| PART I. FINANCIAL INFORMATION | Page |
| Item 1. <u>Financial Statements</u> | 2 |
| <u>Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2014 and 2013</u> | 3 |
| <u>Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2014 and 2013</u> | 4 |
| <u>Condensed Consolidated Balance Sheets as of September 30, 2014, and December 31, 2013</u> | 5 |
| <u>Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2014 and 2013</u> | 6 |
| <u>Notes to Unaudited Condensed Consolidated Financial Statements</u> | 7 |
| Item 2. <u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u> | 24 |
| Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u> | 32 |
| Item 4. <u>Controls and Procedures</u> | 32 |
| PART II. OTHER INFORMATION | |
| Item 1. <u>Legal Proceedings</u> | 32 |
| Item 1A. <u>Risk Factors</u> | 33 |
| Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u> | 33 |
| Item 3. <u>Defaults Upon Senior Securities</u> | 34 |
| Item 4. <u>Mine Safety Disclosures</u> | 34 |
| Item 5. <u>Other Information</u> | 34 |
| Item 6. <u>Exhibits</u> | 34 |
| <u>Signatures</u> | 36 |

Cautionary Note about Forward-Looking Statements

This quarterly report on Form 10-Q contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue, liquidity or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new services, products or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. Forward-looking statements may include the words “may,” “could,” “will,” “estimate,” “intend,” “contingent,” “believe,” “expect” or “anticipate” or other similar words. The forward-looking statements contained herein reflect our current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Actual results may differ materially from those projected in such forward-looking statements due to a number of factors, risks and uncertainties, including the factors that may affect future results set forth in this Current Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2013. We disclaim any obligation to update any forward looking statements as a result of developments occurring after the date of this quarterly report.

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements.

Index

RiceBran Technologies

Condensed Consolidated Statements of Operations

Three and Nine Months Ended September 30, 2014 and 2013

(Unaudited) (in thousands, except share and per share amounts)

| | Three Months Ended | | Nine Months | |
|---|--------------------|------------|-------------|------------|
| | 2014 | 2013 | 2014 | 2013 |
| Revenues | \$10,411 | \$8,725 | \$29,438 | \$26,822 |
| Cost of goods sold | 9,446 | 7,955 | 25,863 | 23,808 |
| Gross profit | 965 | 770 | 3,575 | 3,014 |
| Operating expenses: | | | | |
| Selling, general and administrative | 4,014 | 3,132 | 10,744 | 8,474 |
| Depreciation and amortization | 695 | 302 | 2,272 | 951 |
| Impairment of property | - | - | - | 300 |
| Total operating expenses | 4,709 | 3,434 | 13,016 | 9,725 |
| Loss from operations | (3,744) | (2,664) | (9,441) | (6,711) |
| Other income (expense): | | | | |
| Interest income | 63 | 48 | 100 | 74 |
| Interest expense - accreted on debt converted to equity | - | - | (6,323) | - |
| Interest expense - other | (1,043) | (1,084) | (3,473) | (2,879) |
| Change in fair value of derivative warrant and conversion liabilities | 49 | 576 | (1,679) | (1,918) |
| Foreign currency exchange, net | (203) | (58) | (68) | (346) |
| Loss on extinguishment | - | - | (892) | (526) |
| Financing expense | - | - | (2,072) | (564) |
| Other income | 10 | 22 | 10 | 27 |
| Other expense | (200) | (152) | (318) | (358) |
| Total other income (expense) | (1,324) | (648) | (14,715) | (6,490) |
| Loss before income taxes | (5,068) | (3,312) | (24,156) | (13,201) |
| Income tax benefit | 139 | 636 | 737 | 1,717 |
| Net loss | (4,929) | (2,676) | (23,419) | (11,484) |
| Net loss attributable to noncontrolling interest in Nutra SA | 1,233 | 605 | 2,798 | 1,633 |
| Net loss attributable to RiceBran Technologies shareholders | \$(3,696) | \$(2,071) | \$(20,621) | \$(9,851) |
| Loss per share attributable to RiceBran Technologies shareholders | | | | |
| Basic | \$(0.47) | \$(1.83) | \$(4.05) | \$(9.10) |
| Diluted | \$(0.47) | \$(1.83) | \$(4.05) | \$(9.10) |
| Weighted average number of shares outstanding | | | | |
| Basic | 7,915,349 | 1,129,290 | 5,086,994 | 1,082,452 |
| Diluted | 7,915,349 | 1,129,290 | 5,086,994 | 1,082,452 |

See Notes to Unaudited Condensed Consolidated Financial Statements

Index

RiceBran Technologies
 Condensed Consolidated Statements of Comprehensive Loss
 Three and Nine Months Ended September 30, 2014 and 2013
 (Unaudited) (in thousands)

| | Three Months | | Nine Months | |
|---|--------------|-----------|-------------|------------|
| | 2014 | 2013 | 2014 | 2013 |
| Net loss | \$(4,929) | \$(2,676) | \$(23,419) | \$(11,484) |
| Other comprehensive loss - foreign currency translation, net of tax | (1,044) | (89) | (414) | (901) |
| Comprehensive loss, net of tax | (5,973) | (2,765) | (23,833) | (12,385) |
| Comprehensive loss attributable to noncontrolling interest, net of tax | 1,631 | 648 | 2,920 | 2,074 |
| Total comprehensive loss attributable to RiceBran Technologies shareholders | \$(4,342) | \$(2,117) | \$(20,913) | \$(10,311) |

See Notes to Unaudited Condensed Consolidated Financial Statements

Index

RiceBran Technologies

Condensed Consolidated Balance Sheets

September 30, 2014 and December 31, 2013

(Unaudited) (in thousands, except share amounts)

| | September 30, 2014 | December 31, 2013 |
|--|--------------------------|-------------------------|
| ASSETS | | |
| Current assets: | | |
| Cash and cash equivalents | \$2,025 | \$5,091 |
| Restricted cash | 1,920 | 1,920 |
| Accounts receivable, net of allowance for doubtful accounts of \$587 and \$501 (variable interest entity restricted \$1,947 and \$1,967) | 3,045 | 2,673 |
| Inventories | 3,543 | 2,430 |
| Income and operating taxes recoverable | 524 | 585 |
| Deposits and other current assets | 1,245 | 833 |
| Total current assets | 12,302 | 13,532 |
| Property, net (variable interest entity restricted \$4,267 and \$4,969) | 26,104 | 24,958 |
| Goodwill | 4,720 | 4,139 |
| Intangible assets, net | 3,292 | 1,417 |
| Other long-term assets | 133 | 532 |
| Total assets | \$46,551 | \$44,578 |
| LIABILITIES, TEMPORARY EQUITY AND EQUITY | | |
| Current liabilities: | | |
| Accounts payable | \$3,315 | \$4,489 |
| Accrued salary, wages and benefits | 2,319 | 2,610 |
| Accrued expenses | 4,230 | 3,089 |
| Other liabilities | 428 | 523 |
| Current maturities of debt (variable interest entity nonrecourse \$5,637 and \$6,262) | 5,703 | 8,250 |
| Total current liabilities | 15,995 | 18,961 |
| Long-term debt, less current portion (variable interest entity nonrecourse \$6,947 and \$6,658) | 11,784 | 10,919 |
| Deferred tax liability | 711 | - |
| Derivative warrant liabilities | 1,425 | 1,685 |
| Total liabilities | 29,915 | 31,565 |
| Commitments and contingencies | | |
| Temporary Equity - Redeemable noncontrolling interest in Nutra SA | 3,949 | 7,177 |
| Equity: | | |
| Equity attributable to RiceBran Technologies shareholders: | | |
| Preferred stock, 20,000,000 shares authorized and none issued | - | - |
| Common stock, no par value, 25,000,000 shares authorized, 8,190,512 and 2,832,014 shares issued and outstanding | 255,277 | 227,513 |
| Accumulated deficit | (240,062) | (219,441) |
| Accumulated other comprehensive loss | (2,528) | (2,236) |
| Total equity attributable to RiceBran Technologies shareholders | 12,687 | 5,836 |
| Total liabilities, temporary equity and equity | \$46,551 | \$44,578 |

See Notes to Unaudited Condensed Consolidated Financial Statements

5

Edgar Filing: RiceBran Technologies - Form 424B3

Index

RiceBran Technologies
 Condensed Consolidated Statements of Cash Flows
 Nine Months Ended September 30, 2014 and 2013
 (Unaudited) (in thousands)

| | 2014 | 2013 |
|---|------------|------------|
| Cash flow from operating activities: | | |
| Net loss | \$(23,419) | \$(11,484) |
| Adjustments to reconcile net loss to net cash used in operating activities: | | |
| Depreciation and amortization | 5,079 | 2,975 |
| Stock and share-based compensation | 525 | 524 |
| Change in fair value of derivative warrant and conversion liabilities | 1,679 | 1,918 |
| Loss on extinguishment | 892 | 526 |
| Financing expense | 2,072 | 564 |
| Impairment of property | - | 300 |
| Deferred tax benefit | (737) | (1,717) |
| Interest accreted | 6,909 | 239 |
| Other | 285 | 335 |
| Changes in operating assets and liabilities: | | |
| Accounts receivable | (503) | (253) |
| Inventories | (6) | 463 |
| Accounts payable and accrued expenses | (737) | 2,595 |
| Other | 128 | 493 |
| Net cash used in operating activities | (7,833) | (2,522) |
| Cash flows from investing activities: | | |
| Acquisition of H&N, net of cash acquired | (725) | - |
| Purchases of property | (4,221) | (2,301) |
| Proceeds from sale of property | 23 | 847 |
| Payment for license | - | (1,200) |
| Net cash used in investing activities | (4,923) | (2,654) |
| Cash flows from financing activities: | | |
| Payments of debt | (15,552) | (12,288) |
| Proceeds from issuance of debt, net of issuance costs | 12,782 | 15,163 |
| Proceeds from issuance of convertible debt and related warrants, net of costs | - | 537 |
| Proceeds from issuance of common stock and warrants, net of costs | 12,952 | - |
| Proceeds from sale of membership interest in RBT PRO | - | 1,200 |
| Other | (330) | 300 |
| Net cash provided by financing activities | 9,852 | 4,912 |
| Effect of exchange rate changes on cash and cash equivalents | (162) | (75) |
| Net change in cash and cash equivalents | (3,066) | (339) |
| Cash and cash equivalents, beginning of period | 5,091 | 1,040 |
| Cash and cash equivalents, end of period | \$2,025 | \$701 |
| Supplemental disclosures: | | |
| Cash paid for interest | \$2,239 | \$1,785 |
| Cash paid for income taxes | - | - |

See Notes to Unaudited Condensed Consolidated Financial Statements

6

Index

RiceBran Technologies

Notes to Unaudited Condensed Consolidated Financial Statements

NOTE 1. BASIS OF PRESENTATION

In the opinion of management, the accompanying unaudited condensed consolidated financial statements of RiceBran Technologies and subsidiaries were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC) for reporting on Form 10-Q; therefore, as permitted under these rules, certain footnotes and other financial information included in audited financial statements were condensed or omitted. The interim financial statements contain all adjustments necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented.

These interim financial statements should be read in conjunction with the consolidated financial statements and notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2013. The report of our independent registered public accounting firm that accompanies the audited consolidated financial statements for the years ended December 31, 2013 and 2012, included in that Annual Report on Form 10-K, contains a going concern explanatory paragraph in which our independent registered public accounting firm expressed substantial doubt about our ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

The interim results reported in these condensed consolidated financial statements are not necessarily indicative of the results to be expected for the full fiscal year, or any other future period, and have been prepared assuming we will continue as a going concern based on the realization of assets and the satisfaction of liabilities in the normal course of business.

Certain reclassifications have been made to amounts reported for the prior year to achieve consistent presentation with the current year.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (FASB) issued guidance on revenue from contracts with customers, which supersedes current revenue recognition guidance and most industry-specific guidance. Under the new standard we will recognize revenue from the transfer of goods or services to customers in amounts that reflect the consideration to which we expect to be entitled in exchange for those goods or services. Revenue from a contract that contains multiple performance obligations will be allocated to each performance obligation generally on a relative standalone selling price basis. The guidance is effective for our annual and interim periods beginning in 2017. Early adoption is prohibited. We have not yet determined the impact that the new guidance will have on our results of operations and financial position and have not yet determined the method by which we will adopt the standard in 2017.

NOTE 2. BUSINESS

We are a human food ingredient, nutritional supplement and animal nutrition company focused on value-added processing and marketing of healthy, natural and nutrient dense products derived from raw rice bran (RRB), an underutilized by-product of the rice milling industry. Using our bio-refining business model, we apply our proprietary and patented technologies and intellectual properties to convert RRB into numerous high value products including stabilized rice bran (SRB), rice bran oil (RBO), defatted rice bran (DRB), RiBalance (a complete rice bran nutritional package derived from further processing of SRB), RiSolubles (a highly nutritious, carbohydrate and lipid rich fraction of SRB), RiFiber (a fiber rich derivative of SRB), ProRyza rice bran protein-based products and a variety of other

valuable derivatives extracted from these core products. Our target markets are natural food, functional food, nutraceutical supplement and animal nutrition manufacturers, wholesalers and retailers, both domestically and internationally.

We have two reportable operating segments: (i) USA segment, which manufactures and distributes SRB in various granulations along with Stage II products (described below) and derivatives and formulates and co-packages products and (ii) Brazil segment, which extracts crude RBO and DRB from rice bran, which are then further processed into fully refined rice bran oil for sale internationally and in Brazil, compounded animal nutrition products and a number of valuable human food and animal nutrition products derivatives and co-products. In addition we incur corporate and other expenses not directly attributable to operating segments, which include costs related to our corporate staff, general and administrative expenses including public company expenses, intellectual property, professional fees, and other expenses. No corporate allocations, including interest, are made to the operating segments.

The combined operations of our USA and Brazil segments encompass our bio-refining approach to processing RRB into various high quality, value-added constituents and finished products. Over the past decade, we have developed and optimized our proprietary bio-refining processes to support the production of healthy, natural, hypoallergenic, gluten free, and non-genetically modified ingredients and supplements for use in human meats, baked goods, cereals, coatings, health foods, nutritional supplements, nutraceuticals and high-end animal nutrition and health products.

Index

RiceBran Technologies

Notes to Unaudited Condensed Consolidated Financial Statements

The USA segment produces SRB inside two supplier rice mills in California and one owned facility in Louisiana. A facility located in Lake Charles, Louisiana has been idle since May 2009. The USA segment also includes our Dillon, Montana Stage II facility which produces our Stage II products RiSolubles (a highly nutritious, carbohydrate and lipid rich fraction of SRB), RiFiber (a fiber rich derivative of SRB), RiBalance (a complete rice bran nutritional package derived from further processing SRB), and ProRyza, a family of protein products. Stage II refers to the proprietary processes run at our Dillon, Montana facility and includes products produced at that facility using our patented processes. In January 2014, we completed the acquisition of H&N Distribution Inc., now operating as Healthy Natural, Inc. (H&N), which has been integrated into our USA segment. H&N is a formulator and co-packer of products targeted at customers in the direct marketing, internet sales and retail distribution markets, which operates a facility in Irving, Texas. H&N serves the natural products, nutritional supplement and nutraceutical and functional food (NFF) sectors. We acquired H&N as part of our strategy to vertically integrate our business in order to leverage our proprietary and patented technologies. Certain manufacturing facilities included in our USA segment have proprietary processing equipment and patented technology for the stabilization and further processing of rice bran into finished products. In the three and nine months ended September 30, 2014, approximately 84% of USA segment revenue was from sales of human food products and the remainder was from sales of animal nutrition products.

The Brazil segment consists of the consolidated operations of Nutra SA, whose only operating subsidiary is Irgovel, located in Pelotas, Brazil. Irgovel manufactures RBO and DRB products for both the human ingredient and animal nutrition markets in Brazil and internationally. In refining RBO to an edible grade, several co-products are obtained. One such product is distilled fatty acids, a valuable raw material for the detergent industry. Irgovel recently started production of rice lecithin, which has application in human nutrition, animal nutrition and industrial applications. DRB is compounded with a number of other ingredients to produce complex animal nutrition products which are packaged and sold under Irgovel brands in the Brazilian market, sold as a raw material for further processing into human food ingredients or sold in bulk into the animal nutrition markets in Brazil and neighboring countries. In 2013, approximately 45% of Brazil segment product revenue was from sales of RBO products and 55% was from sales of DRB products. In the three and nine months ended September 30, 2014, approximately 36% of Brazil segment product revenue was from sales of RBO products and the remainder was from sales of DRB products, however Irgovel was shut down for a large portion of these periods to complete the final stages of a capital expansion project, and we expect product mix to return to historical levels in future periods.

NOTE 3. LIQUIDITY AND MANAGEMENT'S PLAN

In 2013 and the first nine months of 2014, we continued to experience losses and negative cash flows from operations which raises substantial doubt about our ability to continue as a going concern. We believe that we now have adequate financial resources to operate our business for the next year and we will be able to obtain additional funds to operate our business, should it be necessary, however, there can be no assurances that our efforts will prove successful. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

We closed an underwritten public offering in December 2013 and completed stock and warrant offerings in the nine months ended September 30, 2014 which together provided us with net proceeds in excess of \$20 million, allowing us to make additional investments in our Brazilian operations and provide cash for corporate purposes. In January 2014, we completed the acquisition of H&N, the operations of which is generating operating cash flows. Our Brazilian subsidiary, Irgovel, shut down operations in the first quarter of 2014 to complete the final stages of a major capital expansion. The shutdown, capital expenditures and restart expenses have been a drain on cash. Operations at Irgovel started again in the second quarter of 2014. Irgovel is expected to begin operating at its newly increased capacity in 2015. We expect Irgovel to begin to generate cash from operations in 2015.

NOTE 4. LOSS PER SHARE (EPS)

Basic EPS is computed by dividing net income (loss) attributable to RiceBran Technologies shareholders by the weighted average number of common shares outstanding during all periods presented. Shares underlying options, warrants and convertible debt are excluded from the basic EPS calculation but are considered in calculating diluted EPS. Nonvested shares that vest solely on the basis of a service condition are not included in the denominator of the computation of basic EPS.

8

Index

RiceBran Technologies

Notes to Unaudited Condensed Consolidated Financial Statements

Diluted EPS is computed by dividing the net income (loss) attributable to RiceBran Technologies shareholders by the weighted average number of shares outstanding during the period increased by the number of additional shares that would have been outstanding if the impact of assumed exercises and conversions is dilutive. The dilutive effect of outstanding options and warrants is calculated using the treasury stock method. The dilutive effect of outstanding convertible debt is calculated using the if-converted method. Nonvested shares that vest solely on the basis of a service condition are included in the denominator of the computation of diluted EPS during their requisite service period under the treasury stock method.

Below are reconciliations of the numerators and denominators in the EPS computations for the three and nine months ended September 30, 2014 and 2013.

| | Three Months Ended | | Nine Months Ended | |
|--|--------------------|------------|-------------------|------------|
| | 2014 | 2013 | 2014 | 2013 |
| NUMERATOR (in thousands): | | | | |
| Basic and diluted - net loss attributable to RiceBran Technologies shareholders | \$(3,696 |) \$(2,071 |) \$(20,621 |) \$(9,851 |
| DENOMINATOR: | | | | |
| Basic EPS - weighted average number of shares outstanding | 7,915,349 | 1,129,290 | 5,086,994 | 1,082,452 |
| Effect of dilutive securities outstanding | - | - | - | - |
| Diluted EPS - weighted average number of shares outstanding | 7,915,349 | 1,129,290 | 5,086,994 | 1,082,452 |
| Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive- | | | | |
| Stock options (average exercise price for the three and nine months ended September 30, 2014 of \$17.15 and \$21.22) | 206,077 | 181,584 | 176,170 | 179,912 |
| Warrants (average exercise price for the three and nine months ended September 30, 2014 of \$5.90 and \$5.99) | 5,227,728 | 716,917 | 4,043,101 | 751,653 |
| Convertible debt | - | 438,754 | - | 452,184 |
| Nonvested stock | 108,251 | - | 36,479 | - |

The impact of potentially dilutive securities outstanding at September 30, 2014 and 2013, was not included in the calculation of diluted EPS for the three and nine months ended September 30, 2014 and 2013 because to do so would be antidilutive. Those securities listed in the table above which were antidilutive for the periods presented, which remain outstanding, could potentially dilute EPS in the future.

NOTE 5. H&N ACQUISITION

In January 2014, we purchased all of the outstanding shares of H&N for \$2.0 million in cash (\$1.8 million paid in January 2014 and \$0.2 million payable upon the resolution of certain contingencies) and promissory notes in the face amount of \$3.3 million, subject to working capital adjustments. H&N is an Irving, Texas-based formulator and co-packer of products targeted at customers in the direct marketing, internet sales and retail distribution markets. H&N serves the natural products, nutritional supplement and nutraceutical and functional food (NFF) sectors. We acquired H&N as part of our strategy to vertically integrate our business in order to leverage our proprietary and patented technologies. The acquisition has been accounted for as a business combination. The results of H&N's operations are included in our consolidated financial statements beginning January 2, 2014, and are included in our

USA segment.

In the first quarter of 2014, we incurred \$0.3 million of acquisition-related costs which are included in selling, general and administrative expenses in the consolidated statements of operations. The following table summarizes the preliminary aggregate purchase price allocation, the consideration transferred to acquire H&N, as well as the amounts of identified assets acquired and liabilities assumed based on the estimated fair value as of the January 2, 2014, acquisition date (in thousands).

9

Index

RiceBran Technologies

Notes to Unaudited Condensed Consolidated Financial Statements

| | |
|--|---------|
| Cash | \$1,800 |
| Cash holdback for contingencies | 200 |
| Convertible notes payable | 2,785 |
| Total fair value of consideration transferred | 4,785 |
| Financial assets, including acquired cash of \$1,075 | 1,314 |
| Inventories | 1,109 |
| Property | 963 |
| Identified intangible asset estimate | 3,848 |
| Deferred income taxes, net | (1,448) |
| Financial liabilities | (1,709) |
| Net recognized amounts of identifiable assets acquired | 4,077 |
| Goodwill - USA segment | \$708 |

The terms of the convertible notes payable are further discussed in Note 10. The fair value of trade receivables at January 2, 2014, was \$0.1 million which equaled the gross amount receivable. The initial accounting for the acquisition is not complete, and is subject to change primarily for certain working capital adjustments provided for in the agreement and conclusions with regard to identified intangibles. Preliminarily, we have assigned a \$3.8 million value to a customer relationship intangible and we are amortizing that intangible over a three year period as follows: \$1.7 million in 2014, \$1.3 million in 2015 and \$0.8 million in 2016. In the three and nine months ended September 30, 2014, we recognized \$0.4 million and \$1.4 million of amortization expense in the USA segment related to this intangible.

Our consolidated revenues include \$3.0 million and \$9.3 million of H&N revenues for the three and nine months ended September 30, 2014. After making a reasonable effort, we have been unable to determine the underlying information required to prepare pro forma information for the three and nine months ended September 30, 2013, as if the H&N acquisition had occurred January 1, 2013.

NOTE 6. REDEEMABLE NONCONTROLLING INTEREST IN NUTRA SA

We hold a variable interest which relates to our equity interest in Nutra SA, LLC (Nutra SA). We are the primary beneficiary of Nutra SA, and as such, Nutra SA's assets, liabilities and results of operations are included in our consolidated financial statements. The other equity holders' interests are reflected in net loss attributable to noncontrolling interest in Nutra SA, in the consolidated statements of operations, and redeemable noncontrolling interest in Nutra SA, in the consolidated balance sheets. Our variable interest in Nutra SA is our Brazil segment. A summary of the carrying amounts of Nutra SA balances included in our consolidated balance sheets follows (in thousands).

| | September 30, 2014 | December 31, 2013 |
|---|--------------------------|-------------------------|
| Cash and cash equivalents | \$ 375 | \$ 1,686 |
| Other current assets (restricted \$1,947 and \$1,967) | 4,629 | 4,546 |
| Property, net (restricted \$4,267 and \$4,969) | 17,012 | 17,672 |
| Goodwill and intangibles, net | 4,242 | 4,812 |
| Other noncurrent assets | 44 | 27 |
| Total assets | \$ 26,302 | \$ 28,743 |

Edgar Filing: RiceBran Technologies - Form 424B3

| | | |
|--|-----------|-----------|
| Current liabilities | \$ 5,281 | \$ 6,514 |
| Current portion of long-term debt (nonrecourse) | 5,637 | 6,262 |
| Long-term debt, less current portion (nonrecourse) | 6,947 | 6,658 |
| Total liabilities | \$ 17,865 | \$ 19,434 |

Nutra SA's debt is secured by its accounts receivable and property. The non-Brazilian entities in our consolidated group do not guarantee any of Nutra SA's debt.

Index

RiceBran Technologies

Notes to Unaudited Condensed Consolidated Financial Statements

A summary of changes in redeemable noncontrolling interest in Nutra SA follows for the three and nine months ended September 30, 2014 and 2013 (in thousands).

| | Three Months | | Nine Months | |
|---|--------------|---------|-------------|---------|
| | Ended | Ended | Ended | Ended |
| | 2014 | 2013 | 2014 | 2013 |
| Redeemable noncontrolling interest in Nutra SA, beginning of period | \$5,604 | \$7,836 | \$7,177 | \$9,262 |
| Investors' interest in net loss of Nutra SA | (1,233) | (605) | (2,798) | (1,633) |
| Investors' interest in other comprehensive loss of Nutra SA | (398) | (43) | (122) | (441) |
| Investors' purchase of additional units of Nutra SA | 120 | 300 | 120 | 300 |
| Accumulated Yield classified as other current liability | (144) | - | (428) | - |
| Redeemable noncontrolling interest in Nutra SA, end of period | \$3,949 | \$7,488 | \$3,949 | \$7,488 |
| Investors' average interest in Nutra SA | 37.8 % | 49.2 % | 41.6 % | 49.1 % |

In December 2010, we entered into a membership interest purchase agreement (MIPA) with AF Bran Holdings-NL LLC and AF Bran Holdings LLC (Investors). As of September 30, 2014 and December 31, 2013, the Investors interest was 37.4% and 45.9%. In the three and nine months ended September 30, 2014, we invested an additional \$1.5 million and \$7.2 million in Nutra SA. We invested an additional \$1.0 million in Nutra SA between October 1, 2014, and November 14, 2014. The Investors' share of Nutra SA's net income (loss) increases (decreases) redeemable noncontrolling interest. We are restricted from competing with Nutra SA and Irgovel in Brazil as further described in the MIPA.

Redeemable noncontrolling interest in Nutra SA is recorded in temporary equity, above the equity section and after liabilities on our consolidated balance sheets, because the Investors have drag along rights which provide the Investors the ability to force a sale of Nutra SA assets in the future. We have assessed the likelihood of the Investors exercising these rights as less than probable at September 30, 2014. We will continue to evaluate the probability of the Investors exercising their drag along rights each reporting period. We will begin to accrete the redeemable noncontrolling interest up to fair value if and when it is probable the Investors will exercise these rights.

Under the limited liability company agreement for Nutra SA (LLC agreement), as amended, any units held by the Investors beginning January 1, 2014, accrue a yield at 4% (the Yield). Commencing with the first quarter of 2014, Nutra SA must make distributions to the Investors quarterly in the amount equal to the previously accrued and unpaid Yield plus any additional distributions owed to the Investors, to the extent there is distributable cash, as defined in the LLC agreement. As of September 30, 2014, our balance sheet includes an other liability of \$0.4 million for Yield accumulated and unpaid. Nutra SA has made no Yield payments.

Following the payment of the Yield, Nutra SA must distribute all distributable cash (as defined in the LLC Agreement) to the members on March 31 of each year as follows: (i) first, to the Investors in an amount equal to 2.3 times the Investors' capital contributions, less the aggregate amount of non-Yield distributions paid to the Investors, (ii) second, to us in an amount equal to twice the capital contributions made by us, less the aggregate amount of distributions paid to us; and (iii) third, to us and the Investors in proportion to our respective membership interests.

Under the LLC agreement, the business of Nutra SA is to be conducted by the manager, currently our CEO, subject to the oversight of the management committee. The management committee is comprised of three of our representatives and two Investor representatives. Upon an event of default or a qualifying event, we will no longer control the management committee and the management committee will include three Investor representatives and two of our

representatives. In addition, following an event of default or a qualifying event, a majority of the members of the management committee may replace the manager of Nutra SA.

As of September 30, 2014, there have been no unwaived events of default. Events of default, as defined in the MIPA and the October 2013 amendment of investment agreements, are:

A Nutra SA business plan deviation, defined as the occurrence in 2014 of a 20% unfavorable variation in two out of three of the following: (i) revenue, (ii) earnings before interest, taxes, depreciation and amortization (EBITDA) or (iii) debt,

A Nutra SA EBITDA default, which is defined as the failure in 2014 to achieve 85% of planned EBITDA for three consecutive quarters,

A material problem, which is defined as a material problem in a facility in 2014 (unrelated to changes in law, weather, etc.) likely to cause a Nutra SA business plan deviation or Nutra SA EBITDA default, which results in damages not at least 80% covered by insurance proceeds,

Index

RiceBran Technologies

Notes to Unaudited Condensed Consolidated Financial Statements

- Failure of Irgovel to meet minimum quarterly processing targets, or
- Failure of Irgovel to achieve EBITDA of at least \$4.0 million in any year beginning in 2015.

As of September 30, 2014, there have been no qualifying events. The LLC agreement defines a qualifying event as any event prior to September 16, 2014, which results, or will result, in (i) a person or group of persons exercising the right to appoint members to our board of directors holding one third or more of the votes of all board members, (ii) the sale, exchange, pledge or use as guarantee of one half or more of our ownership interest in Nutra SA to a third party or (iii) the bankruptcy of RiceBran Technologies or Nutra SA.

The Investors have drag along rights, the right to force the sale of all Nutra SA assets after the earlier of January 1, 2015, or upon the failure to process a certain level of rice bran in the second and third quarters of 2014. The right terminates upon the occurrence of certain events (a \$50 million Nutra SA initial public offering or a change of control, as defined). We may elect to exercise a right of first refusal to purchase the Investors' interest instead of proceeding to a sale.

In evaluating whether we are the primary beneficiary of Nutra SA, we considered the matters which could be put to a vote of the members. Until there is an event of default or a qualifying event, the Investors' rights and abilities, individually or in the aggregate, do not allow them to substantively participate in the operations of Nutra SA. The Investors do not currently have the ability to dissolve Nutra SA or otherwise force the sale of all its assets. They do have drag along rights in the future. We will continue to evaluate our ability to control Nutra SA each reporting period.

Cash provided by operations in our Brazil segment is generally unavailable for distribution to our Corporate and USA segments pursuant to the terms of the LLC agreement.

NOTE 7. INVENTORIES

Inventories are composed of the following (in thousands):

| | September 30, 2014 | December 31, 2013 |
|--------------------|--------------------------|-------------------------|
| Finished goods | \$ 1,314 | \$ 1,194 |
| Work in process | 293 | 546 |
| Raw materials | 1,303 | 441 |
| Packaging supplies | 633 | 249 |
| Total inventories | \$ 3,543 | \$ 2,430 |

NOTE 8. PROPERTY

Property, plant and equipment consist of the following (in thousands):

| | September 30, 2014 | December 31, 2013 |
|------------------------|--------------------------|-------------------------|
| Land | \$ 377 | \$ 382 |
| Furniture and fixtures | 555 | 553 |

Edgar Filing: RiceBran Technologies - Form 424B3

| | | |
|-------------------------------|-----------|-----------|
| Plant | 16,662 | 14,582 |
| Computer and software | 1,568 | 1,437 |
| Leasehold improvements | 563 | 200 |
| Machinery and equipment | 22,191 | 14,557 |
| Construction in progress | 28 | 7,517 |
| Property | 41,944 | 39,228 |
| Less accumulated depreciation | 15,840 | 14,270 |
| Property, net | \$ 26,104 | \$ 24,958 |

Included in accounts payable at September 30, 2014, is \$0.2 million related to amounts payable for capital expansion project additions.

12

Index

RiceBran Technologies

Notes to Unaudited Condensed Consolidated Financial Statements

NOTE 9. GOODWILL

A summary of goodwill activity follows for the three and nine months ended September 30, 2014 and 2013.

| | Three Months | | Nine Months | |
|---|--------------|---------|-------------|---------|
| | Ended | | Ended | |
| | 2014 | 2013 | 2014 | 2013 |
| Goodwill, beginning of period | \$5,099 | \$4,374 | \$4,139 | \$4,773 |
| USA Segment - Acquisition of H&N | 33 | - | 708 | - |
| Brazil segment - Effect of foreign currency translation | (412) | (43) | (127) | (442) |
| Goodwill, end of period | \$4,720 | \$4,331 | \$4,720 | \$4,331 |

NOTE 10. EQUITY, SHARE-BASED COMPENSATION AND LIABILITY WARRANTS

In May 2014, shareholders approved an increase in our authorized shares of common stock from 6,000,000 shares to 25,000,000 shares.

A summary of equity activity for the nine months ended September 30, 2014, (in thousands, except share data) follows.

| | Common Stock | | Accumulated Deficit | Accumulated Other Loss | Comprehensive Total Equity |
|--|--------------|-----------|------------------------|------------------------------|-------------------------------|
| | Shares | Amount | | | |
| Balance, December 31, 2013 | 2,832,014 | \$227,513 | \$ (219,441) | \$ (2,236) | \$5,836 |
| Share-based compensation, employees and directors | 281,620 | 494 | - | - | 494 |
| Stock and warrant offering proceeds, net | 1,605,086 | 7,561 | - | - | 7,561 |
| Warrant issued in private placement offering | - | 430 | - | - | 430 |
| Issuance of shares to former warrant holders and a note holder | 1,688,985 | - | - | - | - |
| Debt conversions | 1,724,461 | 10,109 | - | - | 10,109 |
| Change in classification of warrants to equity from liability | - | 8,902 | - | - | 8,902 |
| Other | 58,346 | 268 | - | - | 268 |
| Foreign currency translation | - | - | - | (292) | (292) |
| Net loss | - | - | (20,621) | - | (20,621) |
| Balance, September 30, 2014 | 8,190,512 | \$255,277 | \$ (240,062) | \$ (2,528) | \$12,687 |

A summary of stock option and warrant activity for the nine months ended September 30, 2014, follows.

| Options Shares Under Options | Weighted Average Exercise Price | Weighted Average Remaining Contractual | Equity and Liability Warrants | | |
|---------------------------------------|--|---|-------------------------------|--|---|
| | | | Shares Under Warrants | Weighted Average Exercise Price | Weighted Average Remaining Contractual |

Edgar Filing: RiceBran Technologies - Form 424B3

| | | | Life (Years) | | | Life (Years) |
|---------------------------------|-----------|----------|-----------------|------------|---------|-----------------|
| Outstanding, December 31, 2013 | 179,437 | \$ 24.28 | 6.2 | 2,406,282 | \$ 6.33 | 4.5 |
| Granted | 141,134 | 4.77 | | 2,986,205 | 5.51 | |
| Exercised | - | - | | - | - | |
| Forfeited, expired or cancelled | (40,465) | 28.55 | | (164,759) | 5.24 | |
| Outstanding, September 30, 2014 | 280,106 | \$ 13.84 | 7.8 | 5,227,728 | \$ 5.90 | 4.3 |
| Exercisable, September 30, 2014 | 133,699 | \$ 22.83 | 5.7 | 5,227,728 | \$ 5.90 | 4.3 |

13

Index

RiceBran Technologies

Notes to Unaudited Condensed Consolidated Financial Statements

The following table summarizes information related to outstanding warrants:

| Range of Exercise Prices | Type of Warrant | As of September 30, 2014 | | | As of December 31, 2013 | | |
|--------------------------|-----------------|--------------------------|---------------------------------|---|-------------------------|---------------------------------|---|
| | | Shares Under Warrants | Weighted Average Exercise Price | Weighted Remaining Contractual Life (Years) | Shares Under Warrants | Weighted Average Exercise Price | Weighted Remaining Contractual Life (Years) |
| \$5.24 | Liability (1) | 426,489 | \$ 5.24 | 3.2 | 591,248 | \$ 5.24 | 2.9 |
| \$5.25 to \$5.87 | Equity | 2,730,439 | 5.41 | 4.6 | - | - | - |
| \$6.55 to \$6.63 | Equity | 2,055,767 | 6.55 | 4.2 | 1,800,001 | 6.55 | 5.0 |
| \$16.00 to \$16.80 | Equity | 12,004 | 16.40 | 0.4 | 12,004 | 16.40 | 4.5 |
| \$46.80 | Equity | 3,029 | 46.80 | 2.9 | 3,029 | 46.80 | 2.9 |
| | | 5,227,728 | \$ 5.90 | 4.3 | 2,406,282 | \$ 6.33 | 4.5 |

(1)The warrants contain full ratchet anti-dilution provisions.

Stock and Warrant Offerings

In January 2014, an underwriter exercised its overallotment rights related to our fourth quarter 2013 public offering. We issued and sold 162,586 shares of common stock for \$5.24 per share and publicly traded warrants to purchase 162,586 shares of common stock (\$6.55 per share exercise price and December 2018 expiration) for \$0.01 per underlying share. In connection with the overallotment exercise, the underwriters on the offering also received a warrant for the purchase of 8,130 shares of common stock (exercise price of \$6.55 per share and December 2018 expiration). The net proceeds from the overallotment exercise were \$0.8 million, after deducting underwriting discounts and commissions and other cash offering expenses of \$0.1 million, and are included in equity.

The first closing on a private placement offering occurred in March 2014. We issued convertible notes in the principal amount of \$4.9 million and warrants for the purchase of up to 1,399,614 shares of common stock (\$5.25 per share exercise price and March 2019 expiration). We contributed \$1.0 million of the \$4.3 million proceeds, net of \$0.6 million of costs, to Nutra SA, and intend to use the remainder of the proceeds for capital projects in the United States and for general corporate purposes. On a fully diluted basis, at issuance we had available shares of common stock for 15.8% of the shares underlying the Warrants. To the extent there were available shares, we allocated proceeds to equity for the warrants (\$0.4 million). We recorded a derivative liability for the warrants to the extent there were not available shares (\$5.0 million). We recorded \$1.1 million in financing expense at closing representing the excess of the amounts recorded for the warrants over the net proceeds from the offering. The convertible notes issued in the offering were initially recorded with a discount equal to the face amount of the notes. As discussed below, in Debt Conversions section, these notes converted in May 2014.

The second closing on a private placement offering occurred in May 2014. We issued convertible notes in the principal amount of \$1.2 million and warrants for the purchase of up to 357,075 shares of common stock, with an exercise price of \$5.25 per share and a May 2019 expiration. We contributed \$0.5 million of the \$1.1 million proceeds, net of \$0.2 million of costs, to Nutra SA, and intend to use the remainder of the proceeds for capital projects in the United States and for general corporate purposes. On a fully diluted basis, at issuance we had no available shares of common stock for the shares underlying these warrants and, as a result, recorded a derivative liability for the fair value of these warrants at issuance (\$2.0 million). We recorded \$1.0 million in financing expense at closing,

representing the excess of the amounts recorded for the warrants over the net proceeds from the offering. The convertible notes issued in the offering were initially recorded with a discount equal to the face amount of the notes. As discussed below, in Debt Conversions section, these notes converted in May 2014.

In June 2014, we issued and sold 1,417,500 shares of common stock for \$5.29 per share and warrants to purchase 708,750 shares of common stock (exercise price of \$5.87 per share and June 2019 expiration) for \$0.01 per underlying share. The underwriters on the offering also received a warrant for the purchase of 85,050 shares of common stock (exercise price of \$6.625 per share and June 2019 expiration). The net proceeds from the offering of \$6.8 million, after deducting underwriting discounts and commissions and other cash offering expenses of \$0.7 million, are included in common stock. We contributed \$3.0 million of the proceeds to Nutra SA, used \$0.8 million of the proceeds to pay all amounts due under the USA segment senior revolving note.

Index

RiceBran Technologies

Notes to Unaudited Condensed Consolidated Financial Statements

In October 2014, we issued and sold 1,181,695 shares of common stock and warrants to purchase 1,181,695 shares of common stock (exercise price of \$5.27 per share, exercisable beginning April 2015, April 2020 expiration) for \$5.40 per unit, where a unit is one share of common stock and a warrant to purchase one share of common stock. The underwriters on the offering also received a warrant for the purchase of 94,536 shares of common stock (exercise price of \$5.27 per share and October 2019 expiration). The estimated net proceeds from the offering of \$5.8 million, after deducting underwriting discounts and commissions and other estimated cash offering expenses of \$0.6 million, will be included in common stock. We intend to use the proceeds for investments in USA segment capital projects and to fund Brazil working capital needs.

Equity Incentive Plan

The board of directors adopted our 2014 equity incentive plan in August 2014, after the plan was approved by shareholders. A total of 1,600,000 shares of common stock were initially reserved for issuance under the plan. Under the terms of the plan, we may grant options to purchase common stock and shares of common stock to officers, directors, employees or consultants providing services on such terms as are determined by the board of directors. Our board of directors administers the plan, determines vesting schedules on plan awards and may accelerate the vesting schedules for award recipients. The options granted under the plan have terms of up to 10 years.

In the third quarter of 2014, in addition to granting the options listed in the summary of stock option and warrant activity above, we issued common stock to directors and officers at a grant date fair value of \$4.91 per share. We issued 52,412 shares which vest in August 2015 (or at the next annual shareholder meeting date if earlier), 44,026 shares which vested in August 2014, 64,938 shares which vest in equal installments over 36 months, and 120,244 shares which vest in August 2017. In the third quarter of 2014, we recognized \$0.3 million in compensation. As of September 30, 2014, we expect to recognize the remaining \$1.0 million of unrecognized compensation over a weighted average period of 2.4 years.

Issuance of Shares to Former Warrant Holders and Note Holder

In the fourth quarter of 2013, the holders of our subordinated convertible notes agreed to amend their notes to reduce the interest rate to 5% from 10%, change the maturity of the notes to July 2016 (if there was a different maturity date) and to remove the conversion feature and antidilution protections upon the closing of an equity raise in excess of \$7.0 million (Modification). Concurrently, certain warrant holders agreed to exchange warrants to purchase 496,060 shares of common stock for the future issuance of 1,554,734 shares of our common stock (Exchange). Most of the warrants impacted (warrants to purchase 441,395 shares) were warrants issued to the note holders when their notes were originally issued and had contained antidilution protections which caused them to be carried at fair value on our balances sheets. The former warrant holders committed to exchange their warrants, which were cancelled upon our closing an equity raise in the fourth quarter of 2013. The fair market value of the shares was recorded in common stock in the fourth quarter of 2013. We issued the shares, as required, after shareholders approved an increase in our authorized shares of common stock in May 2014.

In the fourth quarter of 2013, we also issued \$500,000 of notes to a holder and agreed to issue the holder 134,250 shares of common stock. The fair market value of the shares was recorded in common stock in the fourth quarter of 2013. We issued these shares, as required, after shareholders approved an increase in our authorized shares of common stock in May 2014.

Debt Conversions

In connection with the January 2014 acquisition of H&N, we issued convertible promissory notes in the face amount of \$3.3 million. The notes were due in equal quarterly payments commencing on March 31, 2015, and ending on December 31, 2018 and bore interest at 1% per year until January 2015, 5% per year from February 2015 until January 2016 and 10% per year after January 2016. We recorded the notes at their \$2.2 million fair value and the conversion features at their \$0.6 million fair value on the date of issuance. We accreted the notes at an effective interest rate of 18.9%, until the notes, and accumulated interest thereon, converted into 543,894 shares of common stock upon our issuance of shares to the former warrant holders in the Exchange. The notes converted in May 2014. Upon conversion, we recognized a \$0.9 million loss on extinguishment for the difference between the fair value of the shares issued (\$3.9 million) and the carrying amount of the notes (\$2.4 million) and related conversion feature (\$0.6 million).

The convertible notes issued in the March 2014 and May 2014 closings, due in July 2016, bore interest at 5% interest until the \$6.2 million outstanding on the notes, including accumulated interest thereon (less than \$0.1 million), automatically converted in May 2014, at a conversion price of \$5.25, into 1,180,567 shares of common stock upon shareholders voting to approve an increase in our authorized shares of common stock. When the notes converted, we recognized interest expense of \$6.2 million, to accrete the notes to their face value, and increased equity \$6.2 million.

Index

RiceBran Technologies

Notes to Unaudited Condensed Consolidated Financial Statements

Warrants Reclassified to Equity

Shares of available common stock increased in 2014 as a result of (i) the expiration of certain outstanding warrants and options and (ii) the 19,000,000 share increase in our authorized shares of common stock. As a result, during the second quarter of 2014, we transferred to equity the \$8.9 million fair value of warrants previously classified as derivative liabilities solely due to a lack, on a fully-diluted basis, of available shares of common stock.

Warrants that Contain Antidilution Clauses

As of September 30, 2014, we have two warrant agreements outstanding (with one holder) that contain antidilution clauses. The related warrants are classified as derivative warrant liabilities in our balance sheets. Under the antidilution clauses contained in these warrants, in the event of equity issuances at prices below the exercise prices of these warrants, we may be required to lower the exercise price on these warrants and increase the number of shares underlying these warrants. Equity issuances may include issuances of our common stock, certain awards of options to employees, and issuances of warrants and/or other convertible instruments.

NOTE 11. DEBT

The following table summarizes current and long-term portions of debt (in thousands).

| | September 30, 2014 | December 31, 2013 |
|--------------------------------------|--------------------------|-------------------------|
| Corporate segment: | | |
| Senior revolving note, net | \$ - | \$ 1,988 |
| Subordinated notes, net | 4,780 | 4,261 |
| Other | 123 | - |
| | 4,903 | 6,249 |
| Brazil segment: | | |
| Capital expansion loans | 4,160 | 4,795 |
| Working capital lines of credit | 3,001 | 3,213 |
| Advances on export letters of credit | 1,824 | 2,386 |
| Special tax programs | 3,492 | 2,351 |
| Other | 107 | 175 |
| | 12,584 | 12,920 |
| Total debt | 17,487 | 19,169 |
| Current portion | 5,703 | 8,250 |
| Long-term portion | \$ 11,784 | \$ 10,919 |

USA Segment

See Note 10 for a description of the convertible notes payable issued in the first quarter of 2014 to the former shareholders of H&N and the private placement investors. As discussed further in Note 10, in May 2014, these instruments converted into shares of common stock and the senior revolving note was paid in full with the proceeds from the June 2014 stock and warrant offering. The senior revolving note was due in installments through October 2014.

Subordinated Notes

As of September 30, 2014, subordinated notes in the principal amount of \$6.5 million remain outstanding. The notes bear interest of 5% per year, payable quarterly, and mature in July 2016. We are accreting the notes up to their face value at an average annual interest rate of 22.7%. In connection with the Modification discussed further in Note 10, during the fourth quarter of 2013, the holders of our subordinated convertible notes agreed to amend their notes to reduce the annual interest rate to 5% from 10%, change the maturity of the notes to July 2016 (if there was a different maturity date) and to remove the conversion feature and antidilution protections included in the notes.

Index

RiceBran Technologies

Notes to Unaudited Condensed Consolidated Financial Statements

Brazil Segment

All Brazil segment debt is denominated in the Brazilian Real (R\$), except advances on export letters of credit which are denominated in U.S. Dollars.

Capital Expansion Loans

In December 2011, Irgovel entered into loan agreements with the Bank of Brazil. The annual interest rate on the loans is 6.5%, payable quarterly and the loans mature December 2021. Irgovel must make monthly principal payments under each of the loans. Irgovel used R\$1.5 million of the proceeds for working capital purposes and the remainder for the purchase of equipment and machinery.

In July 2012, Irgovel entered into an agreement with the bank under which it borrowed R\$1.7 million for the purchase of certain equipment at an annual interest rate of 5.5%. Interest is payable quarterly on the amounts outstanding and the maturity date of the loans is July 2019. Irgovel must make monthly principal payments under the loan. The loan is secured by the related equipment.

Working Capital Lines of Credit

Irgovel has working capital lines of credit secured by accounts receivable. The total amount of borrowing cannot exceed 30%-110% of the collateral, depending on the agreement. The annual interest rates on this debt range from 10.4% to 34.8%, and average 22.8%. Principal maturities of amounts outstanding extend through November 2016.

Advances on Export Letters of Credit

Irgovel obtains advances against certain accounts receivable backed by export letters of credit. The annual interest rates on these advances range from 5.9% to 10.0%, and average 8.1%. Principal maturities of amounts outstanding extend through March 2015.

Special Tax Programs

Irgovel has unsecured notes payable for Brazilian federal and social security taxes under special Brazilian government tax programs. During the third quarter of 2014, Irgovel's debt under several notes was consolidated into one note and Irgovel financed an additional \$0.9 million of taxes payable under the programs. Principal and interest payments are due monthly through January 2029. Interest on the notes is payable monthly at the Brazilian SELIC target rate, which was 11.0% at September 30, 2014.

NOTE 12. COMMITMENTS AND CONTINGENCIES

In addition to the matters discussed below, from time to time we are involved in litigation incidental to the conduct of our business. When applicable, we record accruals for contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. While the outcome of lawsuits and other proceedings against us cannot be predicted with certainty, in the opinion of management, individually or in the aggregate, no such lawsuits are expected to have a material effect on our financial position or results of operations. Defense costs are expensed as incurred and are included in professional fees.

Irgovel Purchase

On August 28, 2008, former Irgovel stockholder David Resyng filed an indemnification suit against Irgovel, Osmar Brito and the remaining former Irgovel stockholders (Sellers), requesting: (i) the freezing of the escrow account maintained in connection with the transfer of Irgovel's corporate control to us and the presentation of all documentation related to the transaction, and (ii) damages in the amount of the difference between (a) the sum received by David Resyng in connection with the judicial settlement agreement executed in the action for the partial dissolution of the limited liability company filed by David Resyng against Irgovel and the Sellers and (b) the amount received by the Sellers in connection with the sale of Irgovel's corporate control to us, in addition to moral damages as determined in the court's discretion. The amount of damage claimed by Mr. Resyng is approximately \$3 million.

Index

RiceBran Technologies

Notes to Unaudited Condensed Consolidated Financial Statements

We believe that the filing of the above lawsuit is a fundamental default of the obligations undertaken by the Sellers under the Quotas Purchase Agreement for the transfer of Irgovel's corporate control, executed by and among the Sellers and us on January 31, 2008 (Purchase Agreement). Consequently, we believe that the responsibility for any indemnity, costs and expenses incurred or that may come to be incurred by Irgovel and/or us in connection with the above lawsuit is the sole responsibility of the Sellers.

On February 6, 2009, the Sellers filed a collection lawsuit against us seeking payment of the second installment of the purchase price under the Purchase Agreement, which the Sellers allege is approximately \$1.0 million. We have withheld payment of the second installment pending resolution of the Resyng lawsuit noted above. To date, only Irgovel has received formal legal notice. In addition, the Purchase Agreement requires that all disputes between us and the Sellers be adjudicated through arbitration. As part of the Purchase Agreement, \$2.0 million was deposited into an escrow account to cover contingencies with the net remaining funds payable to the Sellers upon resolution of all contingencies. We believe any payout due to the lawsuit will be made out of the escrow account. As of September 30, 2014 and December 31, 2013, the balance in the escrow account was \$1.9 million and is included in restricted cash in our balance sheets. There is an escrow liability related to the lawsuit in accrued expenses on our balance sheets. When the escrow account was funded, we established an accrued liability equal to the amount of the escrow for contingencies and the net balance due to the Sellers under the terms of the Purchase Agreement. As of September 30, 2014, after paying or accruing specific pre-acquisition liabilities, a balance of \$1.6 million remains accrued to settle as yet unidentified contingencies. We believe that there is no additional material exposure as any amounts determined to be owed as a result of the above noted litigation and contingencies will be covered by the escrow account.

Diabco Life Sciences, LLC

In January 2012, we filed a complaint in the Superior Court of California, Sacramento County, seeking damages arising out of Diabco Life Sciences, LLC's (Diabco) breach of a 2008 promissory note in the principal amount of \$0.5 million. At trial in August 2013, Diabco stipulated that total damages through July 2013, including interest and late fees, amounted to \$0.9 million. In September 2013, the court issued its tentative statement of decision indicating that judgment will be entered in our favor in the amount of \$0.9 million as of July 2013, plus interest. In January 2014, the court issued its final judgment in the amount of \$1.0 million. Diabco filed a notice of appeal which was dismissed in October 2014. We have no receivable from Diabco recorded in the accompanying financial statements, as recovery of the judgment is not reasonably assured.

Index

RiceBran Technologies

Notes to Unaudited Condensed Consolidated Financial Statements

NOTE 13. SEGMENT INFORMATION

The tables below present segment information for the periods identified and provide reconciliations of segment information to total consolidated information (in thousands).

| <u>Three Months Ended September 30, 2014</u> | Corporate | USA | Brazil | Consolidated |
|--|-------------|----------|------------|--------------|
| Revenues | \$- | \$5,895 | \$4,516 | \$ 10,411 |
| Cost of goods sold | - | 3,867 | 5,579 | 9,446 |
| Gross profit | - | 2,028 | (1,063) | 965 |
| Depreciation and amortization (in selling, general and administrative) | (14) | (502) | (179) | (695) |
| Other operating expense | (1,624) | (1,095) | (1,295) | (4,014) |
| Income (loss) from operations | \$(1,638) | \$431 | \$(2,537) | \$(3,744) |
| Net income (loss) attributable to RiceBran Technologies | \$(1,723) | \$431 | \$(2,404) | \$(3,696) |
| Interest expense | 274 | - | 769 | 1,043 |
| Depreciation (in cost of goods sold) | - | 255 | 842 | 1,097 |
| Purchases of property | 15 | 661 | 258 | 934 |
| <u>Nine Months Ended September 30, 2014</u> | Corporate | USA | Brazil | Consolidated |
| Revenues | \$- | \$17,636 | \$11,802 | \$ 29,438 |
| Cost of goods sold | - | 12,360 | 13,503 | 25,863 |
| Gross profit | - | 5,276 | (1,701) | 3,575 |
| Depreciation and amortization (in selling, general and administrative) | (38) | (1,699) | (535) | (2,272) |
| Other operating expense | (4,593) | (2,891) | (3,260) | (10,744) |
| Income (loss) from operations | \$(4,631) | \$686 | \$(5,496) | \$(9,441) |
| Net income (loss) attributable to RiceBran Technologies | \$(16,201) | \$686 | \$(5,106) | \$(20,621) |
| Interest expense | 7,664 | - | 2,132 | 9,796 |
| Depreciation (in cost of goods sold) | - | 768 | 2,039 | 2,807 |
| Purchases of property | 131 | 1,519 | 2,571 | 4,221 |

Index

RiceBran Technologies

Notes to Unaudited Condensed Consolidated Financial Statements

Three Months Ended September 30, 2013

| | Corporate | USA | Brazil | Consolidated |
|--|-------------|---------|-------------|--------------|
| Revenues | \$ - | \$3,065 | \$5,660 | \$ 8,725 |
| Cost of goods sold | - | 2,332 | 5,623 | 7,955 |
| Gross profit | - | 733 | 37 | 770 |
| Depreciation and amortization (in selling, general and administrative) | (6) | (119) | (177) | (302) |
| Other operating expense | (1,292) | (622) | (1,218) | (3,132) |
| Loss from operations | \$ (1,298) | \$ (8) | \$ (1,358) | \$ (2,664) |
| Net loss attributable to RiceBran Technologies shareholders | \$ (1,433) | \$ (8) | \$ (630) | \$ (2,071) |
| Interest expense | 666 | - | 418 | 1,084 |
| Depreciation (in cost of goods sold) | - | 207 | 468 | 675 |
| Purchases of property | 6 | 19 | 1,026 | 1,051 |

Nine Months Ended September 30, 2013

| | Corporate | USA | Brazil | Consolidated |
|--|-------------|---------|-------------|--------------|
| Revenues | \$ - | \$9,099 | \$17,723 | \$ 26,822 |
| Cost of goods sold | - | 6,895 | 16,913 | 23,808 |
| Gross profit | - | 2,204 | 810 | 3,014 |
| Depreciation and amortization (in selling, general and administrative) | (17) | (358) | (576) | (951) |
| Other operating expense | (3,627) | (1,743) | (3,404) | (8,774) |
| Income (loss) from operations | \$ (3,644) | \$ 103 | \$ (3,170) | \$ (6,711) |
| Net income (loss) attributable to RiceBran Technologies shareholders | \$ (8,255) | \$ 103 | \$ (1,699) | \$ (9,851) |
| Interest expense | 1,541 | - | 1,338 | 2,879 |
| Depreciation (in cost of goods sold) | - | 665 | 1,359 | 2,024 |
| Purchases of property | 12 | 147 | 2,142 | 2,301 |

The tables below present segment information for selected balance sheet accounts (in thousands).

| | Corporate | USA | Brazil | Consolidated |
|---------------------------------|-----------|---------|---------|--------------|
| <u>As of September 30, 2014</u> | | | | |
| Inventories | \$ - | \$2,167 | \$1,376 | \$ 3,543 |
| Property, net | 150 | 8,942 | 17,012 | 26,104 |
| Goodwill | - | 708 | 4,012 | 4,720 |
| Intangible assets, net | - | 3,062 | 230 | 3,292 |
| Total assets | 3,668 | 16,580 | 26,303 | 46,551 |
| <u>As of December 31, 2013</u> | | | | |
| Inventories | - | 870 | 1,560 | 2,430 |
| Property, net | 55 | 7,231 | 17,672 | 24,958 |
| Goodwill | - | - | 4,139 | 4,139 |
| Intangible assets, net | - | 745 | 672 | 1,417 |
| Total assets | 6,039 | 9,796 | 28,743 | 44,578 |

Corporate segment total assets include cash, restricted cash, property and other assets.

Index

RiceBran Technologies

Notes to Unaudited Condensed Consolidated Financial Statements

The following table presents revenue by geographic area for the three and nine months ended September 30, 2014 and 2013 (in thousands).

| | Three Months | | Nine Months | |
|---------------------|--------------|---------|-------------|----------|
| | 2014 | 2013 | 2014 | 2013 |
| United States | \$5,948 | \$3,052 | \$16,986 | \$9,714 |
| Brazil | 4,063 | 4,048 | 11,030 | 13,845 |
| Other international | 400 | 1,625 | 1,422 | 3,263 |
| Total revenues | \$10,411 | \$8,725 | \$29,438 | \$26,822 |

NOTE 14. FAIR VALUE MEASUREMENT

The fair value of cash and cash equivalents, accounts and other receivables and accounts payable approximates their carrying value due to their shorter maturities. As of September 30, 2014, the fair value of our USA segment debt (Level 3 measurement) is approximately \$0.2 million higher than the \$4.7 million carrying value of that debt, based on current market rates for similar debt with similar maturities. The fair value of our Brazil segment debt (Level 3 measurement) approximates the carrying value of that debt based on the current market rates for similar debt with similar maturities.

Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Certain assets and liabilities are presented in the financial statements at fair value. Assets and liabilities measured at fair value on a recurring basis include derivative warrant and conversion liabilities. Assets and liabilities measured at fair value on a non-recurring basis may include property.

We assess the inputs used to measure fair value using a three-tier hierarchy based on the extent to which inputs used in measuring fair value are observable in the market:

Level 1 – inputs include quoted prices for identical instruments and are the most observable.

Level 2 – inputs include quoted prices for similar assets and observable inputs such as interest rates, currency exchange rates and yield curves.

Level 3 – inputs are not observable in the market and include management’s judgments about the assumptions market participants would use in pricing the asset or liability.

For instruments measured using Level 3 inputs, a reconciliation of the beginning and ending balances is disclosed.

The following tables summarize the fair values by input hierarchy of items measured at fair value on a recurring basis on our consolidated balance sheets (in thousands):

| | Level 1 | Level 2 | Level 3 | Total |
|--|---------|---------|-----------|-----------|
| Total liabilities at fair value, as of September 30, 2014 - derivative warrant liabilities | \$ - | \$ - | \$(1,425) | \$(1,425) |
| Total liabilities at fair value, as of December 31, 2013 - derivative warrant liabilities | \$ - | \$ - | \$(1,685) | \$(1,685) |

Edgar Filing: RiceBran Technologies - Form 424B3

Warrants accounted for as derivative liabilities are valued using the lattice model each reporting period and the resultant change in fair value is recorded in the statements of operations. The lattice model requires us to assess the probability of future issuance of equity instruments at a price lower than the current exercise price of the warrants. The risk-free interest rate is determined by reference to the treasury yield curve rate of instruments with the same term as the warrant. Additional assumptions that were used to calculate fair value follow.

| | September 30, 2014 | December 31, 2013 |
|-------------------------|---|---|
| Risk-free interest rate | 0.1% - 0.9% (0.9% weighted average) | 0.1% - 0.6% (0.5% weighted average) |
| Expected volatility | 98.8% - 99.4% (99.2% weighted average) | 104.5% - 108.0% (106.8% weighted average) |

Index

RiceBran Technologies

Notes to Unaudited Condensed Consolidated Financial Statements

The following tables summarize the changes in level 3 items measured at fair value on a recurring basis (in thousands):

| | Fair Value as of Beginning of Period | Total Realized and Unrealized Gains (Losses) (1) | Issuance of New Instruments | Net Transfers (Into) Out of Level 3 | Fair Value, at End of Period | Change in Unrealized Gains (Losses) on Instruments Still Held |
|---|---|--|-----------------------------------|--|--|--|
| <u>Nine Months Ended September 30, 2014</u> | | | | | | |
| Derivative warrant liability | \$ (1,685) | \$ (1,621) | \$ (7,021) | \$ 8,902 (2) | \$ (1,425) | \$ 76 |
| Derivative conversion liability | - | (58) | (589) | 647 (3) | - | - |
| Total Level 3 fair value | \$ (1,685) | \$ (1,679) | \$ (7,610) | \$ 9,549 | \$ (1,425) | \$ 76 |
| <u>Nine Months Ended September 30, 2013</u> | | | | | | |
| Derivative warrant liability | \$ (4,520) | \$ (1,413) | \$ (575) | \$ - | \$ (6,508) | \$ (1,413) |
| Derivative conversion liability | (2,199) | (505) | (588) | 99 (3) | (3,193) | (896) |
| Total Level 3 fair value | \$ (6,719) | \$ (1,918) | \$ (1,163) | \$ 99 | \$ (9,701) | \$ (2,309) |

(1) Included in change in fair value of derivative warrant and conversion liabilities in our consolidated statements of operations.

(2) Represents transfers to equity as a result of increases in authorized and unissued shares of common stock available for settlement of certain warrants.

(3) Represents reduction in conversion liability as a result of debt conversions.

The following tables summarize the fair values by input hierarchy of items measured at fair value in our balance sheets on a nonrecurring basis (in thousands):

| | As of December 31, 2013 | | | 2013 Impairment | |
|-------------------|----------------------------|---------|---------|--------------------|--------|
| | Level 1 | Level 2 | Level 3 | Total | Losses |
| Property, net (1) | \$ - | \$ - | \$ 394 | \$ 394 | \$ 300 |
| Property, net | \$ - | \$ - | \$ 394 | \$ 394 | \$ 300 |

(1) Machinery and equipment not currently in use was evaluated for impairment and as a result was written down to estimated fair value in the first quarter of 2013.

NOTE 15. RELATED PARTY TRANSACTIONSTransactions with Baruch Halpern

Entities beneficially owned by Baruch Halpern, a director, invested \$2.6 million in our subordinated convertible notes and related warrants prior to 2013. In all periods presented we paid less than \$0.1 million of interest on subordinated notes beneficially owned by Mr. Halpern. The terms of the notes beneficially owned by Mr. Halpern were changed in the Modification.

In connection with the Exchange, warrants beneficially owned by Mr. Halpern for the purchase of up to 185,714 shares of common stock (\$14.00 per share exercise price with a July 31, 2017 expiration), related to the subordinated convertible notes were cancelled in exchange for 634,679 shares of our common stock (with a fair value of \$2.9 million at time of the Exchange). The shares were not required to be issued until after our shareholders approved an increase in our authorized shares of common stock, which occurred on May 30, 2014.

Index

RiceBran Technologies

Notes to Unaudited Condensed Consolidated Financial Statements

In connection with the Exchange, other warrants beneficially owned by Mr. Halpern for the purchase of up to 45,683 shares of common stock (\$14.00 per share exercise prices and expirations between January 2017 and August 2017) were cancelled in exchange for 75,377 shares of our common stock (with a fair value of \$0.3 million at time of the Exchange). The shares were not required to be issued until after our shareholders approved an increase in our authorized shares of common stock, which occurred on May 30, 2014.

Transactions with W. John Short

W. John Short, our chief executive officer and director, invested in our subordinated convertible notes and related warrants \$50 thousand in January 2012 and \$25 thousand in April 2013. In all periods presented, we paid less than \$10 thousand of interest on subordinated notes beneficially owned by Mr. Short. In June 2013, Mr. Short made an election to be paid in stock, rather than cash, for interest accruing under the notes from February 2013 through June 2014. In connection with the election, in 2013 we issued a PIK warrant with 234 underlying shares of common stock, and increased the shares underlying Mr. Short's convertible notes by 234 shares as payment for interest accruing under the convertible notes from February 2013 through October 2013. The terms of the notes beneficially owned by Mr. Short were impacted by the Modification.

In connection with the Exchange, warrants beneficially owned by Mr. Short for the purchase of up to 2,020 shares of common stock (\$14.00 per share exercise prices and expirations of July 2017 and May 2018), including the PIK warrant, were cancelled in exchange for 6,674 shares of our common stock. The shares were not required to be issued until after our shareholders approved an increase in our authorized shares of common stock, which occurred on May 30, 2014.

Transactions with Mark McKnight

In January 2014, we purchased all of the outstanding shares of H&N Distribution, Inc. (H&N) for \$2.0 million in cash, plus convertible promissory notes for \$3.3 million. Mark McKnight, our current senior vice president of contract manufacturing, and his wife collectively owned a majority interest in H&N prior to the acquisition. In connection with our acquisition of H&N, Mark McKnight received \$0.7 million in cash and a convertible promissory note for \$1.4 million and Nicole McKnight, his wife, received \$0.7 million in cash and a convertible promissory note for \$1.4 million. We had the option to pay principal and accrued interest under the notes in either cash or in our common stock, however, if we issued shares to our former warrants holders upon an increase in authorized shares, under the terms of the Exchange, then we were required to settle any outstanding balance on the notes through the issuance of shares of our common stock. On May 30, 2014, we issued 225,925 shares of common stock to settle Mark McKnight's note and 225,925 shares of common stock to settle Nicole McKnight's note. The notes were converted at a conversion price of \$6.00 per share.

In January 2014, we entered into a \$0.1 million, 5% unsecured, promissory note with Nicole McKnight. We paid all principal and interest due under the note in October 2014.

During the three and nine months ended September 30, 2013, prior to the acquisition, we had product sales to H&N totaling \$0.2 million and \$0.6 million.

NOTE 16. INCOME TAXES

In connection with our accounting for the acquisition of H&N in January 2014, we established deferred tax liabilities of \$1.4 million. These deferred tax liabilities primarily relate to intangibles recorded for financial reporting purposes,

which are not deductible for tax purposes. We expect to utilize the benefit of our net operating loss carryforwards and current net operating losses against the taxable income as these deferred tax liabilities reverse. As a result, we reduced the valuation allowance on \$0.2 million of our United States net operating loss carryforwards and recognized a deferred income tax benefit in the three and nine months ended September 30, 2014.

Utilization of net operating loss carryforwards may be subject to substantial annual limitations due to the “change in ownership” provisions of the Internal Revenue Code of 1986, as amended and similar state regulations. The annual limitations may result in the expiration of substantial net operating loss carryforwards before utilization. We have not completed the necessary analyses to determine the amount of such limitation. However, we expect any limitations will not impair our ability to realize the tax benefit recognized in 2014.

NOTE 17. CONCENTRATION OF CREDIT RISK

One USA segment customer accounted for approximately 29% of our consolidated revenues for the nine months ended September 30, 2014 and 7% of our consolidated revenues for the nine months ended September 30, 2013. This customer accounted for approximately 2% of our consolidated accounts receivable balances at September 30, 2014 and 2013.

Index

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis addresses material changes in the results of operations and financial condition of RiceBran Technologies and subsidiaries for the periods presented. This discussion and analysis should be read in conjunction with the consolidated financial statements, the related notes thereto, and management's discussion and analysis of results of operations and financial condition included in our Annual Report on Form 10-K, for the year ended December 31, 2013.

In 2013 and the first nine months of 2014, we experienced losses and negative cash flows from operations on a consolidated basis which raises substantial doubt about our ability to continue as a going concern. We believe that we now have adequate financial resources to operate our business for the next year and we will be able to obtain additional funds to operate our business, should it be necessary. However, there can be no assurances that our efforts will prove successful. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

We closed an underwritten public offering in December 2013 and completed stock and warrant offerings in the nine months ended September 30, 2014 which together provided us with net proceeds in excess of \$20 million, allowing us to make additional investments in our Brazilian operations and provide cash for corporate purposes. In January 2014, we completed the acquisition of H&N Distribution Inc., now operating as Healthy Natural, Inc. (H&N), the operations of which is generating operating cash flows. Our Brazilian subsidiary, Irgovel, shut down operations in the first quarter of 2014 to complete the final stages of a major capital expansion. The shutdown and capital expenditures have been a drain on cash. Operations at Irgovel started again in the second quarter of 2014. Irgovel is expected to begin operating at its newly increased capacity in 2015. We expect Irgovel to begin to generate cash from operations in 2015.

We are a human food ingredient, nutritional supplement and animal nutrition company focused on value-added processing and marketing of healthy, natural and nutrient dense products derived from raw rice bran (RRB), an underutilized by-product of the rice milling industry. Using our bio-refining business model, we apply our proprietary and patented technologies and intellectual properties to convert RRB into numerous high value products including stabilized rice bran (SRB), rice bran oil (RBO), defatted rice bran (DRB), RiBalance (a complete rice bran nutritional package derived from further processing of SRB), RiSolubles (a highly nutritious, carbohydrate and lipid rich fraction of SRB), RiFiber (a fiber rich derivative of SRB), ProRyza rice bran protein-based products and a variety of other valuable derivatives extracted from these core products. Our target markets are natural food, functional food, nutraceutical supplement and animal nutrition manufacturers, wholesalers and retailers, both domestically and internationally.

We have two reportable operating segments: (i) USA segment, which manufactures and distributes SRB in various granulations along with Stage II products (described below) and derivatives and formulates and co-packages products and (ii) Brazil segment, which extracts crude RBO and DRB from rice bran, which are then further processed into fully refined rice bran oil for sale internationally and in Brazil, compounded animal nutrition products and a number of valuable human food and animal nutrition products derivatives and co-products. In addition we incur corporate and other expenses not directly attributable to operating segments, which include costs related to our corporate staff, general and administrative expenses including public company expenses, intellectual property, professional fees, and other expenses. No corporate allocations, including interest, are made to the operating segments.

The combined operations of our USA and Brazil segments encompass our bio-refining approach to processing RRB into various high quality, value-added constituents and finished products. Over the past decade, we have developed and optimized our proprietary bio-refining processes to support the production of healthy, natural, hypoallergenic, gluten free, and non-genetically modified ingredients and supplements for use in human meats, baked goods, cereals, coatings, health foods, nutritional supplements, nutraceuticals and high-end animal nutrition and health products.

The USA segment produces SRB inside two supplier rice mills in California and one owned facility in Louisiana. A facility located in Lake Charles, Louisiana has been idle since May 2009. The USA segment also includes our Dillon, Montana Stage II facility which produces our Stage II products RiSolubles (a highly nutritious, carbohydrate and lipid rich fraction of SRB), RiFiber (a fiber rich derivative of SRB), RiBalance (a complete rice bran nutritional package derived from further processing SRB), and ProRyza, a family of protein products. Stage II refers to the proprietary processes run at our Dillon, Montana facility and includes products produced at that facility using our patented processes. In January 2014, we completed the acquisition of H&N which has been integrated into our USA segment. H&N is a formulator and co-packer of products targeted at customers in the direct marketing, internet sales and retail distribution markets, which operates a facility in Irving, Texas. H&N serves the natural products, nutritional supplement and nutraceutical and functional food (NFF) sectors. We acquired H&N as part of our strategy to vertically integrate our business in order to leverage our proprietary and patented technologies. Certain manufacturing facilities included in our USA segment have proprietary processing equipment and patented technology for the stabilization and further processing of rice bran into finished products. In the three and nine months ended September 30, 2014, approximately 84% of USA segment revenue was from sales of human food products and the remainder was from sales of animal nutrition products.

Index

The Brazil segment consists of the consolidated operations of Nutra SA, whose only operating subsidiary is Irgovel, located in Pelotas, Brazil. Irgovel manufactures RBO and DRB products for both the human ingredient and animal nutrition markets in Brazil and internationally. In refining RBO to an edible grade, several co-products are obtained. One such product is distilled fatty acids, a valuable raw material for the detergent industry. Irgovel recently started production of rice lecithin, which has application in human nutrition, animal nutrition and industrial applications. DRB is compounded with a number of other ingredients to produce complex animal nutrition products which are packaged and sold under Irgovel brands in the Brazilian market, sold as a raw material for further processing into human food ingredients or sold in bulk into the animal nutrition markets in Brazil and neighboring countries. In 2013, approximately 45% of Brazil segment product revenue was from sales of RBO products and 55% was from sales of DRB products. In the three and nine months ended September 30, 2014, approximately 36% of Brazil segment product revenue was from sales of RBO products and the remainder was from sales of DRB products, however Irgovel was shut down for a large portion of these periods to complete the final stages of a capital expansion project, and we expect product mix to return to historical levels in future periods.

Results of OperationsTHREE MONTHS ENDED SEPTEMBER 30, 2014 and 2013

Consolidated net loss attributable to RiceBran Technologies shareholders for the three months ended September 30, 2014, was \$3.7 million, or \$0.47 per share, compared to a loss of \$2.1 million, or \$1.83 per share, for the three months ended September 30, 2013.

Revenue and Gross Profit

Revenues (in thousands):

| | Three Months Ended September 30, | | | | | |
|----------------|----------------------------------|---------------------------|---------|---------------------------|---------|-------------|
| | 2014 | % of Total Revenues | 2013 | % of Total Revenues | Change | % Change |
| USA segment | \$5,895 | 56.6 | \$3,065 | 35.1 | \$2,830 | 92.3 |
| Brazil segment | 4,516 | 43.4 | 5,660 | 64.9 | (1,144) | (20.2) |
| Total revenues | \$10,411 | 100.0 | \$8,725 | 100.0 | \$1,686 | 19.3 |

Consolidated revenues for the three months ended September 30, 2014, were \$10.4 million compared to \$8.7 million in the prior year period, an increase of \$1.7 million, or 19.3%.

USA segment revenues increased \$2.8 million, or 92.3% in 2014 compared to 2013. Animal feed product revenues decreased \$0.4 million on lower volume while human nutrition product revenues increased \$3.2 million, in large part due to increased sales in the human functional food market as a result of the acquisition of H&N. The decline in animal feed revenue was primarily attributable to reduced sales to two large, but low margin customers. We continue to focus on increasing the higher margin human nutrition product revenue in our mix of revenues.

Brazil segment revenues decreased \$1.1 million, or 20.2% in 2014 compared to 2013. Revenues decreased less than \$0.1 million as a result of the 0.8% decline in the average exchange rate between these periods. On a local currency basis, prior to translation into US dollars, Brazil segment revenues decreased 20.6% year over year. Revenues were negatively affected by the Irgovel plant shut down that began in January 2014. The plant was shut down until April 2014 for expansion of the rice bran oil extractor, the key functional part of the plant, as well as installation of a new desolventizing/toasting system. Production began again in April 2014 on a limited basis. During the 2014 first

quarter, inventory available for sale was limited to certain animal feed products that utilized DRB that had been stockpiled prior to the shutdown. Production yields were limited by the quality of rice bran stored during shut down. Bran stored for long periods develops higher fatty acid levels requiring additional refinement. Bran normally is processed within days of receipt. During the 2014 third quarter, Irgovel experienced production downtimes due to an equipment failure and was unable to secure raw bran as a result of disengaging with bran suppliers during the shutdown and working capital issues, which reduced production and product available for sale. Irgovel plans to shut down for two weeks in December 2014 for annual maintenance and to resume operations in 2015 at its new increased capacity. In the fourth quarter, with the additional contributions of capital, we have not experienced bran supply issues.

Index

Gross profit (in thousands):

| | Three Months Ended September 30, | | | | | |
|--------------------|----------------------------------|----------------|-------|----------------|---------|--------------------------|
| | 2014 | Gross Profit % | 2013 | Gross Profit % | Change | Change in Gross Profit % |
| USA segment | \$2,028 | 34.4 | \$733 | 23.9 | \$1,295 | 10.5 |
| Brazil segment | (1,063) | (23.5) | 37 | 0.7 | (1,100) | (24.2) |
| Total gross profit | \$965 | 9.3 | \$770 | 8.8 | \$195 | 0.5 |

Consolidated gross profit in the third quarter of 2014 increased \$0.2 million, or 0.5 percentage points, to \$1.0 million for the three months ended September 30, 2014, compared to \$0.8 million in the prior year period.

The USA segment gross profit increased \$1.3 million, to \$2.0 million in 2014, from \$0.7 million in 2013. The improvement was attributable to increased human nutrition product revenues derived from the acquisition of H&N and the resulting shift in sales mix from animal to human. Raw bran prices were relatively unchanged quarter over quarter.

Brazil segment gross profit declined \$1.1 million, or 24.2 percentage points. As noted above, the Irgovel plant was shut down in January 2014. Production began again at the beginning of the second quarter on a limited basis and raw bran processing levels steadily increased throughout the second quarter of 2014. Processing levels are expected to reach approximately 150% of pre-expansion raw bran processing levels consistently in 2015. The amount of raw bran processed in the third quarter of 2014 was significantly lower than in the third quarter of 2013 due to the shutdown and subsequent restart issues. In addition, the Irgovel plant experienced a mechanical breakdown in September resulting in a complete plant shutdown of approximately one week which negatively impacted quarterly revenues.

Operating Expenses (in thousands):

| | Three Months Ended September 30, 2014 | | | |
|-------------------------------------|---------------------------------------|---------|---------|--------------|
| | Corporate | USA | Brazil | Consolidated |
| Selling, general and administrative | \$1,624 | \$1,095 | \$1,295 | \$4,014 |
| Depreciation and amortization | 14 | 502 | 179 | 695 |
| Total operating expenses | \$1,638 | \$1,597 | \$1,474 | \$4,709 |

| | Three Months Ended September 30, 2013 | | | |
|-------------------------------------|---------------------------------------|-------|---------|--------------|
| | Corporate | USA | Brazil | Consolidated |
| Selling, general and administrative | \$1,292 | \$622 | \$1,218 | \$3,132 |
| Depreciation and amortization | 6 | 119 | 177 | 302 |
| Total operating expenses | \$1,298 | \$741 | \$1,395 | \$3,434 |

| | Favorable (Unfavorable) Change | | | |
|-------------------------------------|--------------------------------|---------|--------|--------------|
| | Corporate | USA | Brazil | Consolidated |
| Selling, general and administrative | \$(332) | \$(473) | \$(77) | \$(882) |
| Depreciation and amortization | (8) | (383) | (2) | (393) |
| Total operating expenses | \$(340) | \$(856) | \$(79) | \$(1,275) |

Consolidated operating expenses were \$4.7 million for the third quarter of 2014, compared to \$3.4 million for the third quarter of 2013, an increase of \$1.3 million.

Corporate segment selling, general and administrative expenses (SG&A) increased \$0.3 million. A \$0.2 million increase in share-based board compensation was offset by a \$0.2 million reduction in legal expenses. Bonus expense increased \$0.2 million and the remainder of the increase related to additional investor relations costs.

USA segment SG&A expenses also increased \$0.5 million. Additional expenses related to operations and management of H&N, acquired in January 2014 were approximately \$0.3 million. The remainder of the increase related to increased to bonus and travel expenses.

Brazil segment SG&A increased \$0.1 million primarily relating to bonuses earned for meeting capital expansion project target dates.

Index

USA segment depreciation and amortization expense increased \$0.4 million due to amortization of a customer relationship intangible asset of \$3.8 million established in January 2014 upon the acquisition of H&N. Amortization of the intangible is occurring on an accelerated basis over a three year period.

Other Income (Expense) (in thousands):

| | Three Months Ended September 30, 2014 | | | |
|---|--|------|-----------|--------------|
| | Corporate | USA | Brazil | Consolidated |
| Interest income | \$- | \$ - | \$63 | \$ 63 |
| Interest expense | (274) | - | (769) | (1,043) |
| Foreign currency exchange, net | - | - | (203) | (203) |
| Change in fair value of derivative warrant and conversion liabilities | 49 | - | - | 49 |
| Other | - | - | (190) | (190) |
| Other income (expense) | \$(225) | \$ - | \$(1,099) | \$(1,324) |

| | Three Months Ended September 30, 2013 | | | |
|---|--|------|----------|--------------|
| | Corporate | USA | Brazil | Consolidated |
| Interest income | \$- | \$ - | \$48 | \$ 48 |
| Interest expense | (666) | - | (418) | (1,084) |
| Foreign currency exchange, net | - | - | (58) | (58) |
| Change in fair value of derivative warrant and conversion liabilities | 576 | - | - | 576 |
| Other | (46) | - | (84) | (130) |
| Other income (expense) | \$(136) | \$ - | \$(512) | \$(648) |

| | Favorable (Unfavorable) Change | | | |
|---|--------------------------------|------|----------|--------------|
| | Corporate | USA | Brazil | Consolidated |
| Interest income | \$- | \$ - | \$15 | \$ 15 |
| Interest expense | 392 | - | (351) | 41 |
| Foreign currency exchange, net | - | - | (145) | (145) |
| Change in fair value of derivative warrant and conversion liabilities | (527) | - | - | (527) |
| Other | 46 | - | (106) | (60) |
| Other income (expense) | \$(89) | \$ - | \$(587) | \$(676) |

Consolidated other expense was \$1.3 million for the third quarter of 2014, compared to other expense of \$0.6 million for the third quarter of 2013.

The Corporate segment experienced a \$0.4 million decrease in interest expense as a result of lower average outstanding borrowings. The convertible notes issued in the private placement offering March 2014 and May 2014 closings, automatically converted in May 2014 upon shareholders approving an increase in our authorized shares of common stock and we paid off our senior revolving note in June 2014.

The Corporate segment also experienced a \$0.5 million decrease in income from the change in the fair value of derivative warrant and conversion liabilities. Our liability warrants and conversion liabilities are valued using the lattice model each reporting period and the resulting change in fair value is recorded in the statements of operations. The lattice model requires us to assess the probability of future issuance of equity instruments at a price lower than the current exercise price of the warrants and make certain other assumptions. The changes in our stock price between periods contributed to the change. During the third quarter of 2014 we had no conversion liabilities.

In the Brazil segment, the \$0.4 million increase in interest expense was a result of an increase in average debt and interest bearing payables outstanding and the \$0.1 million increase in foreign currency exchange losses, related to the Brazil segment's US Dollar denominated debt.

NINE MONTHS ENDED SEPTEMBER 30, 2014 and 2013

Consolidated net loss attributable to RiceBran Technologies shareholders for the nine months ended September 30, 2014, was \$20.6 million, or \$4.05 per share, compared to a loss of \$9.9 million, or \$9.10 per share, for the nine months ended September 30, 2013.

IndexRevenue and Gross Profit

Revenues (in thousands):

| | Nine Months Ended September 30, | | | | | |
|----------------|---------------------------------|---------------------------|----------|---------------------------|---------|-------------|
| | 2014 | % of Total Revenues | 2013 | % of Total Revenues | Change | % Change |
| USA segment | \$17,636 | 59.9 | \$9,099 | 33.9 | \$8,537 | 93.8 |
| Brazil segment | 11,802 | 40.1 | 17,723 | 66.1 | (5,921) | (33.4) |
| Total revenues | \$29,438 | 100.0 | \$26,822 | 100.0 | \$2,616 | 9.8 |

Consolidated revenues for the nine months ended September 30, 2014, were \$29.4 million compared to \$26.8 million in the prior year period, an increase of \$2.6 million, or 9.8%.

USA segment revenues increased \$8.5 million, or 93.8%, in 2014 compared to 2013. Animal feed product revenues decreased \$1.4 million on lower volume while human nutrition product revenues increased \$9.9 million, in large part due to increased sales in the human functional food market as a result of the acquisition of H&N. The decline in animal feed revenue was primarily attributable to reduced sales to two large, but low margin customers. We continue to focus on increasing the higher margin human nutrition product revenues.

Brazil segment revenues decreased \$5.9 million, or 33.4%, in 2014 compared to 2013. Revenues decreased \$1.0 million as a result of the 7.7% decrease in the average exchange rate between these periods. On a local currency basis, prior to translation into US dollars, Brazil segment revenues decreased 28.2% year over year. Revenues were negatively affected by the Irgovel plant shut down that began in January 2014. The plant was shut down until April 2014 for expansion of the rice bran oil extractor, the key functional part of the plant, as well as installation of a new desolventizing/toasting system. Production began again in April 2014 on a limited basis. During the 2014 first quarter of the shutdown period, inventory available for sale was limited to certain animal feed products that utilized DRB that had been stockpiled prior to the shutdown. Production yields were limited by the quality of rice bran stored during shut down. Bran stored for long periods develops higher fatty acid levels requiring additional refinement. Bran normally is processed within days of receipt. During the 2014 third quarter, Irgovel experienced production downtimes due to an equipment failure and was unable to secure raw bran as a result of disengaging with bran suppliers during the shut down and working capital issues, which reduced production and product available for sale. Irgovel plans to shut down for two weeks in December 2014 for annual maintenance and to resume operations in 2015 at its new increased capacity. In the fourth quarter, with the additional contributions of capital, we have not experienced bran supply issues.

Gross profit (in thousands):

| | Nine Months Ended September 30, | | | | | |
|--------------------|---------------------------------|----------------------|---------|----------------------|---------|--------------------------------------|
| | 2014 | Gross Profit % | 2013 | Gross Profit % | Change | Change in Gross Profit % |
| USA segment | \$5,276 | 29.9 | \$2,204 | 24.2 | \$3,072 | 5.7 |
| Brazil segment | (1,701) | (14.4) | 810 | 4.6 | (2,511) | (19.0) |
| Total gross profit | \$3,575 | 12.1 | \$3,014 | 11.2 | \$561 | 0.9 |

Consolidated gross profit in the first nine months of 2014 increased \$0.6 million, or 0.9 percentage points, to \$3.6 million for the nine months ended September 30, 2014, compared to \$3.0 million in the prior year period.

The USA segment gross profit increased \$3.1 million, to \$5.3 million in 2014, from \$2.2 million in 2013. The improvement was attributable to increased human nutrition product revenues derived from the acquisition of H&N and the resulting shift in sales mix from animal to human. Raw bran prices were relatively flat between periods.

Index

Brazil segment gross profit declined \$2.5 million between periods. As noted previously, the Irgovel plant was shut down in January 2014. Production began again at the beginning of the second quarter on a limited basis raw bran processing levels steadily increased through the second quarter of 2014. Processing levels are expected to reach approximately 150% of pre-expansion raw bran processing levels consistently in 2015. The amount of raw bran processed in the first nine months of 2014 was significantly lower than in the first nine months of 2013 due to the shutdown and subsequent restart issues.

Operating Expenses (in thousands):

| | Nine Months Ended September 30, 2014 | | | |
|-------------------------------------|--------------------------------------|---------|---------|--------------|
| | Corporate | USA | Brazil | Consolidated |
| Selling, general and administrative | \$4,593 | \$2,891 | \$3,260 | \$ 10,744 |
| Depreciation and amortization | 38 | 1,699 | 535 | 2,272 |
| Total operating expenses | \$4,631 | \$4,590 | \$3,795 | \$ 13,016 |

| | Nine Months Ended September 30, 2013 | | | |
|-------------------------------------|--------------------------------------|---------|---------|--------------|
| | Corporate | USA | Brazil | Consolidated |
| Selling, general and administrative | \$3,627 | \$1,443 | \$3,404 | \$ 8,474 |
| Impairment of property | - | 300 | - | 300 |
| Depreciation and amortization | 17 | 358 | 576 | 951 |
| Total operating expenses | \$3,644 | \$2,101 | \$3,980 | \$ 9,725 |

| | Favorable (Unfavorable) Change | | | |
|-------------------------------------|--------------------------------|-----------|--------|--------------|
| | Corporate | USA | Brazil | Consolidated |
| Selling, general and administrative | \$(966) | \$(1,448) | \$144 | \$ (2,270) |
| Impairment of property | - | 300 | - | 300 |
| Depreciation and amortization | (21) | (1,341) | 41 | (1,321) |
| Total operating expenses | \$(987) | \$(2,489) | \$185 | \$ (3,291) |

Consolidated operating expenses were \$13.0 million for the first nine months of 2014, compared to \$9.7 million for the first nine months of 2013, an increase of \$3.3 million.

Corporate segment selling, general and administrative expenses (SG&A) increased \$1.0 million. The first nine months of 2014 included \$0.3 of acquisition costs related to the closing of the H&N acquisition in January 2014. The first nine months of 2014 also included additional bonus expense of \$0.6 million and \$0.2 million of additional legal, financial advisor and investor relations costs.

USA segment SG&A expenses increased \$1.4 million. Additional expenses related to the operations and management of H&N, acquired in January 2014 were approximately \$0.8 million. The prior year period included a \$0.3 million gain on sale of property. The remainder of the increase related primarily to increased bonus and travel.

Brazil segment SG&A decreased \$0.1 million as a result of the decline in the average foreign exchange rate between periods.

USA segment depreciation and amortization expense increased \$1.3 million due to amortization of a customer relationship intangible asset of \$3.8 million established in January 2014 upon the acquisition of H&N. The intangible is amortizing on an accelerated basis over a three year period.

IndexOther Income (Expense) (in thousands):

| | Nine Months Ended September 30, 2014 | | | |
|---|--------------------------------------|------|-----------|--------------|
| | Corporate | USA | Brazil | Consolidated |
| Interest income | \$- | \$ - | \$100 | \$ 100 |
| Interest expense | (7,664) | - | (2,132) | (9,796) |
| Foreign currency exchange, net | - | - | (68) | (68) |
| Change in fair value of derivative warrant and conversion liabilities | (1,679) | - | - | (1,679) |
| Loss on extinguishment | (892) | - | - | (892) |
| Financing expense | (2,072) | - | - | (2,072) |
| Other | - | - | (308) | (308) |
| Other income (expense) | \$(12,307) | \$ - | \$(2,408) | \$ (14,715) |

| | Nine Months Ended September 30, 2013 | | | |
|---|--------------------------------------|------|-----------|--------------|
| | Corporate | USA | Brazil | Consolidated |
| Interest income | \$- | \$ - | \$74 | \$ 74 |
| Interest expense | (1,541) | - | (1,338) | (2,879) |
| Foreign currency exchange, net | - | - | (346) | (346) |
| Change in fair value of derivative warrant and conversion liabilities | (1,918) | - | - | (1,918) |
| Loss on extinguishment | (526) | - | - | (526) |
| Financing expense | (564) | - | - | (564) |
| Other | (63) | - | (268) | (331) |
| Other income (expense) | \$(4,612) | \$ - | \$(1,878) | \$ (6,490) |

| | Favorable (Unfavorable) Change | | | |
|---|--------------------------------|------|----------|--------------|
| | Corporate | USA | Brazil | Consolidated |
| Interest income | \$- | \$ - | \$26 | \$ 26 |
| Interest expense | (6,123) | - | (794) | (6,917) |
| Foreign currency exchange, net | - | - | 278 | 278 |
| Change in fair value of derivative warrant and conversion liabilities | 239 | - | - | 239 |
| Loss on extinguishment | (366) | - | - | (366) |
| Financing expense | (1,508) | - | - | (1,508) |
| Other | 63 | - | (40) | 23 |
| Other income (expense) | \$(7,695) | \$ - | \$(530) | \$ (8,225) |

Consolidated other expense was \$14.7 million for the first nine months of 2014, compared to other expense of \$6.5 million for the first nine months of 2013.

The Corporate segment experienced a \$6.1 million increase in interest expense. The convertible notes issued in the March 2014 and May 2014 private placement offering closings, automatically converted in May 2014 upon shareholders approving an increase in our authorized shares of common stock. When the notes converted, we recognized noncash charge for interest expense of \$6.2 million, to accrete the notes to their face value, and increased equity \$6.2 million.

The Corporate segment also experienced a \$0.2 million decrease in expense from the change in the fair value of derivative warrant and conversion liabilities. Our liability warrants and conversion liabilities are valued using the lattice model each reporting period and the resulting change in fair value is recorded in the statements of operations. The lattice model requires us to assess the probability of future issuance of equity instruments at a price lower than the current exercise price of the warrants and make certain other assumptions. During the third quarter of 2014 we had no conversion liabilities.

Corporate segment loss on extinguishment increased \$0.4 million between periods. In 2014, the \$0.9 million of loss on extinguishment in the second quarter was a result of the conversion of the notes payable issued in the acquisition of H&N. Upon conversion, we recognized a \$0.9 million loss on extinguishment for the difference between the fair value of the shares issued (\$3.9 million) and the carrying amount of the notes (\$2.4 million) and related conversion feature (\$0.6 million), as described further in Note 10 to the consolidated financial statements.

Corporate segment financing expense increased \$1.5 million. In 2014, the \$2.1 million of financing expense in the first nine months was associated with the March 2014 and May 2014 private placement issuance of convertible notes and related warrants and represented the excess of the values assigned to the equity warrants and derivative liability warrants, at issuance, over the net proceeds from issuance, as described further in Note 10 to the consolidated financial statements.

Index

In the Brazil segment the \$0.8 million increase in interest expense was a result of an increase in average debt and interest bearing payables outstanding and the \$0.4 million decrease in foreign currency exchange losses, related to the Brazil segment's US Dollar denominated debt.

Liquidity and Capital Resources

With respect to liquidity and capital resources, we manage the Brazil segment, consisting currently of our plant in Brazil, separately from our U.S. based Corporate and USA segments. Cash on hand at our Brazil segment is generally unavailable for distribution to our Corporate and USA segments pursuant to the terms of the limited liability company agreement for Nutra SA. Cash used in operating activities for the nine months ended September 30, 2014 and 2013, is presented below by segment (in thousands).

| | Nine Months Ended September 30, 2014 | | |
|---|---|-----------|--------------|
| | Corporate and USA | Brazil | Consolidated |
| Net loss | \$(15,515) | \$(7,904) | \$(23,419) |
| Adjustments to reconcile net loss to net cash used in operations: | | | |
| Depreciation and amortization | 2,504 | 2,575 | 5,079 |
| Change in fair value of derivative warrant and conversion liabilities | 1,679 | - | 1,679 |
| Loss on extinguishment | 892 | - | 892 |
| Financing expense | 2,072 | - | 2,072 |
| Impairment of property | - | - | - |
| Other adjustments, net | 6,738 | 244 | 6,982 |
| Changes in operating assets and liabilities | (1,096) | (22) | (1,118) |
| Net cash used in operating activities | \$(2,726) | \$(5,107) | \$(7,833) |

| | Nine Months Ended September 30, 2013 | | |
|---|---|-----------|--------------|
| | Corporate and USA | Brazil | Consolidated |
| Net loss | \$(8,152) | \$(3,332) | \$(11,484) |
| Adjustments to reconcile net loss to net cash used in operations: | | | |
| Depreciation and amortization | 1,040 | 1,935 | 2,975 |
| Change in fair value of derivative warrant and conversion liabilities | 1,918 | - | 1,918 |
| Loss on extinguishment | 526 | - | 526 |
| Financing expense | 564 | - | 564 |
| Impairment of property | 300 | - | 300 |
| Other adjustments, net | 752 | (1,371) | (619) |
| Changes in operating assets and liabilities | 388 | 2,910 | 3,298 |
| Net cash used in operating activities | \$(2,664) | \$142 | \$(2,522) |

On a combined basis, the Corporate and USA segments used \$2.8 million of cash in operating activities in the first nine months of 2014. We expect H&N, acquired in January 2014, will generate positive operating cash flows in 2014, and the combined Corporate and USA cash flows will improve over the remainder of 2014. During the first nine months of 2014 we paid \$0.3 million in H&N acquisition costs which are included in cash flows from operations.

In the first nine months of 2014, proceeds from public and private offerings, net of cash costs, totaled \$13.0 million. During the first quarter of 2014, we paid \$0.5 million to redeem stock which had been issued to a lender in payment of fees. In the second quarter of 2014, we paid our secured debt in full and thus have paid our senior secured debt in

full. On May 31, 2014, all of our convertible debt outstanding, with a face amount of \$9.4 million, converted into shares of our common stock and as of September 30, 2014, no convertible debt remains outstanding. We believe that more traditional commercial bank debt financing at significantly lower interest rates may be available as our performance improves in the last quarter of 2014.

Index

In October 2014, we issued and sold 1,181,695 shares of common stock and warrants to purchase 1,181,695 shares of common stock (exercise price of \$5.27 per share, exercisable beginning April 2015, April 2020 expiration) for \$5.40 per unit, where a unit is one share of common stock and a warrant to purchase one share of common stock. The underwriters on the offering also received a warrant for the purchase of 94,536 shares of common stock (exercise price of \$5.27 per share and October 2019 expiration). We intend to use the estimated net proceeds from the offering of \$5.8 million, after deducting underwriting discounts and commissions and other estimated cash offering expenses of \$0.6 million for investments in USA segment capital projects and to fund Brazil working capital needs.

During the first nine months of 2014, the Corporate segment made additional investments in Nutra SA (Brazil segment) of \$7.2 million, and in the period from October 1, 2014 to November 14, 2014 invested an additional \$1.0 million.

The Brazil segment used \$5.1 million in operating cash in the first nine months of 2014, compared to generating \$0.1 million of operating cash in the first nine months of 2013. The increased use of cash was a direct result of the planned facility shut down. Irgovel completed the final stages of a capital expansion project involving installation of new equipment and improvements to existing infrastructure. As a result of the project, the Irgovel facility was shut down approximately ten weeks in the first quarter of 2014, while certain new equipment was brought on line. Upon restarting the plant in April, the plant experienced excessive downtime and inefficiencies during the “debugging” of plant production processes. Where possible, we stockpiled certain inventory for sale during the period the plant was shut down. However, this inventory was not adequate to timely fulfill all outstanding orders during this period. Facility shut down and subsequent restart expenses, as well as lack of adequate working capital in some periods, adversely affected our operating results through September 30, 2014. Operations at Irgovel started again in the second quarter of 2014. Irgovel is expected to begin operating at its newly increased capacity in 2015. We expect Irgovel to begin to generate cash from operations in 2015.

Off-Balance Sheet Arrangements

We have not entered into any transactions with unconsolidated entities whereby we have financial guarantees, subordinated retained interests, derivative instruments or other contingent arrangements that expose us to material continuing risk, contingent liabilities, or any other obligation under a variable interest in an unconsolidated entity that provides us financing and liquidity support or market risk or credit risk support.

Critical Accounting Policies

Our discussion and analysis of our financial condition and results of operations are based upon unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses and disclosures on the date of the financial statements. On an ongoing basis, we evaluate the estimates, including, but not limited to, those related to revenue recognition. We use authoritative pronouncements, historical experience and other assumptions as the basis for making judgments. Actual results could differ from those estimates.

For further information about other critical accounting policies, see the discussion of critical accounting policies in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (FASB) issued guidance on revenue from contracts with customers, which supersedes current revenue recognition guidance and most industry-specific guidance. Under the new standard we will recognize revenue from the transfer of goods or services to customers in amounts that reflect the

consideration to which we expect to be entitled in exchange for those goods or services. Revenue from a contract that contains multiple performance obligations will be allocated to each performance obligation generally on a relative standalone selling price basis. The guidance is effective for our annual and interim periods beginning in 2017. Early adoption is prohibited. We have not yet determined the impact that the new guidance will have on our results of operations and financial position and have not yet determined the method by which we will adopt the standard in 2017.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Not applicable

Item 4. Controls and Procedures

32

Index

We evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

Information regarding certain legal proceedings to which we are a party can be found in the description of legal proceedings contained in our Annual Report on Form 10-K for the year ended December 31, 2013, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014, and is incorporated herein by reference. There have not been any material developments with respect to such proceedings during the quarter to which this report on Form 10-Q relates.

In addition to the matters described below, we are involved in or subject to, or may become involved in or subject to, routine litigation, claims, disputes, proceedings and investigations in the ordinary course of business. While the outcome of lawsuits and other proceedings against us cannot be predicted with certainty, in the opinion of management, individually or in the aggregate, no such lawsuits are expected to have a material effect on our financial position or results of operations. When applicable, we record accruals for contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated.

Diabco Life Sciences, LLC

In January 2012, we filed a complaint in the Superior Court of California, Sacramento County, seeking damages arising out of Diabco Life Sciences, LLC's (Diabco) breach of a 2008 promissory note in the principal amount of \$0.5 million. At trial August 2013, Diabco stipulated that total damages through July 2013, including interest and late fees, amounted to \$0.9 million. In September 2013, the court issued its tentative statement of decision indicating that judgment will be entered in our favor in the amount of \$0.9 million as of July 2013, plus interest. In January 2014, the court issued its final judgment in the amount of \$1.0 million. Diabco filed a notice of appeal which was dismissed in October 2014. We have no receivable from recorded in the accompanying financial statements, as recovery of the judgment is not reasonably assured.

Item 1A. Risk Factors

In addition to the other information set forth in this Quarterly Report, you should carefully consider the factors discussed in Part I, "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2013, which could materially affect our business, financial condition, liquidity or future results. The risks described in our Annual Report on Form 10-K are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, liquidity or future results.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

During the quarter ended September 30, 2014, we issued the securities described below without registration under the Securities Act. Unless otherwise indicated below, the securities were issued pursuant to the private placement

Edgar Filing: RiceBran Technologies - Form 424B3

exemption provided by Section 4(a)(2) of the Securities Act of 1933, as amended. All issuances below were made without any public solicitation, to a limited number of persons and were acquired for investment purposes only.

We granted shares of common stock to employees and directors as summarized in the table which follows.

| Date of Issuance | Shares of Common Stock | Recipients | Vesting Period |
|------------------|------------------------------|------------|--|
| August 19, 2014 | 52,412 | Directors | August 19, 2015, or one day prior to our next annual meeting, if earlier |
| August 19, 2014 | 44,026 | Directors | Immediate |
| August 19, 2014 | 64,938 | Executives | Three years, in 36 monthly instalments |
| August 19, 2014 | 120,244 | Executives | Three years, on August 19, 2017 |

Index

We issued shares of common stock under agreements with consultants and vendors as summarized in the table which follows.

| Date of Issuance | Shares of Common Stock | Vesting Period |
|------------------|------------------------------|----------------|
| July 1, 2014 | 1,875 | Immediate |
| July 31, 2014 | 25,000 | Immediate |

Effective August 1, 2014, pursuant to an asset sale and purchase agreement with NukaCha Inc., we issued 15,000 shares of our common stock in exchange for the “NukaCha” trademark, and certain other assets.

We issued options as described in the table which follows.

| Date of Issuance | Recipients | Number of Underlying Shares of Common Stock | Exercise Price Per Share | Vesting Period | Expiration |
|------------------|------------|---|-----------------------------------|--|-----------------|
| August 19, 2014 | Executives | 68,634 | \$ 4.77 | Three years, in 36 monthly instalments | August 19, 2024 |
| August 19, 2014 | Employees | 72,500 | \$ 4.77 | Three years, in 36 monthly instalments | August 19, 2024 |

Item 3. Defaults upon Senior Securities

None

Item 4. Mine Safety Disclosures

None

Item 5. Other Information

None

Item 6. Exhibits

The following exhibits are attached hereto and filed herewith:

34

Index

Exhibit

Number Description of Exhibit

| | |
|----------------|---|
| 4.1 | Form of Warrant (incorporated herein by reference to exhibits previously filed on registrant's current report on 8-K, filed on September 30, 2014) |
| 10.1 * | RiceBran Technologies 2014 Equity Incentive Plan (incorporated herein by reference to exhibits previously filed on registrant's current report on Form 8-K, filed on August 25, 2014) |
| 10.2 * | Securities Purchase Agreement (incorporated herein by reference to exhibits previously filed on registrant's current report on 8-K, filed on October 1, 2014) |
| 10.3 * | Form of Registration Rights Agreement (incorporated herein by reference to exhibits previously filed on registrant's current report on 8-K, filed on October 1, 2014) |
| 31.1 | Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| 31.2 | Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| 32.1 | Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 101.INS (1) | XBRL Instance Document |
| 101.SCH (1) | XBRL Taxonomy Extension Schema Document |
| 101.CAL (1) | XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF (1) | XBRL Taxonomy Extension Calculation Definition Document |
| 101.LAB (1) | XBRL Taxonomy Extension Calculation Label Document |
| 101.PRE (1) | XBRL Taxonomy Extension Calculation Presentation Document |

(1) XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

* Indicates a management contract or compensatory plan, contract or arrangements in which any director or executive officer may participate.

Index

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: November 14, 2014

/s/ W. John Short
W. John Short
Chief Executive
Officer

/s/ J. Dale Belt
Jerry Dale Belt
Chief Financial
Officer

Index

Exhibit 31.1

Certification of Principal Executive Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, W. John Short, certify that:

1) I have reviewed this quarterly report on Form 10-Q of RiceBran Technologies;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report was prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting;

The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)

Edgar Filing: RiceBran Technologies - Form 424B3

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's disclosure internal control over financial reporting.

Dated: November 14, 2014 /s/ W. John Short

Name: W. John
Short
Title: Chief
Executive Officer

Index

Exhibit 31.2

Certification of Principal Financial Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Jerry Dale Belt, certify that:

1) I have reviewed this quarterly report on Form 10-Q of RiceBran Technologies;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report was prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting;

The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)

Edgar Filing: RiceBran Technologies - Form 424B3

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's disclosure internal control over financial reporting.

Dated: November 14, 2014 /s/ J. Dale Belt

Name: Jerry
Dale Belt
Title: Chief
Financial
Officer

38

Index

Exhibit 32.1

Certification of Principal Executive Officer and Principal Financial Officer
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of RiceBran Technologies (the Company) for the period ended September 30, 2014, as filed with the Securities and Exchange Commission on the date hereof (the Report), each of the undersigned, in the capacities and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

- 1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934;
and
- 2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Company.

Dated: November 14, 2014

/s/ W. John Short
W. John Short
Chief Executive
Officer

/s/ J. Dale Belt
Jerry Dale Belt
Chief Financial
Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

The foregoing certification is being furnished in accordance with Securities and Exchange Commission Release No. 34-47551 and shall not be considered filed as part of the Form 10-Q.